<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title>BMC Medical Genetics</journal-title><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-10-50</article-id><article-id pub-id-type="pmid">19497121</article-id><article-id pub-id-type="doi">10.1186/1471-2350-10-50</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>ACE (I/D) polymorphism and response to treatment in coronary artery disease: a comprehensive database and meta-analysis involving study quality evaluation</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Kitsios</surname><given-names>Georgios</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>GKitsios@tuftsmedicalcenter.org</email></contrib><contrib id="A2" corresp="yes" contrib-type="author"><name><surname>Zintzaras</surname><given-names>Elias</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>ezintzaras@tuftsmedicalcenter.org</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Biomathematics, University of Thessaly School of Medicine, Larissa, Greece</aff><aff id="I2"><label>2</label>Center for Clinical Evidence Synthesis, Institute for Clinical Research and Health Policy Studies, Department of Medicine, Tufts Medical Center, Tufts University School of Medicine, 800 Washington Street, Tufts MC #63, Boston, MA 02111, USA</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>4</day><month>6</month><year>2009</year></pub-date><volume>10</volume><fpage>50</fpage><lpage>50</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/10/50"/><history><date date-type="received"><day>12</day><month>9</month><year>2008</year></date><date date-type="accepted"><day>4</day><month>6</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Kitsios and Zintzaras; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Kitsios and Zintzaras; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Kitsios Georgios GKitsios@tuftsmedicalcenter.org </dc:author><dc:title> ACE (I/D) polymorphism and response to treatment in coronary artery disease: a comprehensive database and meta-analysis involving study quality evaluation </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>BMC Medical Genetics 10(1): 50-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2350(2009)10:1&#x0003c;50&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2350</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>The role of angiotensin-converting enzyme (<italic>ACE</italic>) gene insertion/deletion (<italic>I/D</italic>) polymorphism in modifying the response to treatment modalities in coronary artery disease is controversial.</p></sec><sec sec-type="methods"><title>Methods</title><p>PubMed was searched and a database of 58 studies with detailed information regarding <italic>ACE I/D </italic>polymorphism and response to treatment in coronary artery disease was created. Eligible studies were synthesized using meta-analysis methods, including cumulative meta-analysis. Heterogeneity and study quality issues were explored.</p></sec><sec><title>Results</title><p>Forty studies involved invasive treatments (coronary angioplasty or coronary artery by-pass grafting) and 18 used conservative treatment options (including anti-hypertensive drugs, lipid lowering therapy and cardiac rehabilitation procedures). Clinical outcomes were investigated by 11 studies, while 47 studies focused on surrogate endpoints. The most studied outcome was the restenosis following coronary angioplasty (34 studies). Heterogeneity among studies (p &#x0003c; 0.01) was revealed and the risk of restenosis following balloon angioplasty was significant under an additive model: the random effects odds ratio was 1.42 (95% confidence interval:1.07&#x02013;1.91). Cumulative meta-analysis showed a trend of association as information accumulates. The results were affected by population origin and study quality criteria. The meta-analyses for the risk of restenosis following stent angioplasty or after angioplasty and treatment with angiotensin-converting enzyme inhibitors produced non-significant results. The allele contrast random effects odds ratios with the 95% confidence intervals were 1.04(0.92&#x02013;1.16) and 1.10(0.81&#x02013;1.48), respectively. Regarding the effect of <italic>ACE I/D </italic>polymorphism on the response to treatment for the rest outcomes (coronary events, endothelial dysfunction, left ventricular remodeling, progression/regression of atherosclerosis), individual studies showed significance; however, results were discrepant and inconsistent.</p></sec><sec><title>Conclusion</title><p>In view of available evidence, genetic testing of <italic>ACE I/D </italic>polymorphism prior to clinical decision making is not currently justified. The relation between <italic>ACE </italic>genetic variation and response to treatment in CAD remains an unresolved issue. The results of long-term and properly designed prospective studies hold the promise for pharmacogenetically tailored therapy in CAD.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Coronary artery disease (CAD), including its most severe complication, myocardial infarction (MI), is a complex disorder resulting from the interaction between genetic and environmental factors. Despite extensive efforts using the candidate gene approach or genome-wide linkage studies, the responsible molecular and genetic determinants remain largely unidentified [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Recently, genome-wide association studies provided more convincing evidence for CAD-associated genomic loci, generating cautious optimism for disentangling the disease pathophysiology and defining novel targets for treatment [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>CAD mortality has been falling consistently in western countries, as a result of population-wide improvements in cardiovascular risk factors and modern cardiology treatments for CAD patients [<xref ref-type="bibr" rid="B4">4</xref>]. Nevertheless, a considerable inter-individual variability in response to the various treatment modalities for CAD, both invasive and pharmacological, has been described [<xref ref-type="bibr" rid="B5">5</xref>]. Given the large number of interventions currently available for the treatment and prevention of CAD and the large number of patients eligible to receive them, even small sources of variation in efficacy and safety have important implications for public health. An important source of variability in response to treatment is attributed to the patient's genetic profile [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>].</p><p>Among the most studied genes for its implication in pathogenesis of CAD and related outcomes is angiotensin converting enzyme (<italic>ACE</italic>) gene, located on chromosome 17q23 [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B8">8</xref>]. The genetic polymorphism in intron 16, characterized by an <italic>insertion </italic>(<italic>I</italic>) or a <italic>deletion </italic>(<italic>D</italic>) of a 287 noncoding base pair Alu repeat sequence (dbSNP rs4646994) has been correlated with the levels of circulating, intracellular and heart tissue activity of ACE [<xref ref-type="bibr" rid="B9">9</xref>]. Apart from conferring susceptibility, the <italic>ACE </italic>gene has been also proposed to play a role in modifying the effect of various treatments in CAD. This potential modifying role has been investigated by numerous studies on several treatment-outcome settings. However, the available evidence published to date is weak, owing to sparseness of data or disagreements among studies. The aim of this study is to summarize the available <italic>ACE I/D </italic>and response-to-treatment studies for CAD and, where applicable, to quantify the effect size of the estimated risk associated with this polymorphism by meta-analysis.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Selection of studies</title><p>A comprehensive search of the PubMed database from its inception through March 2008 was conducted. We combined search terms for <italic>ACE </italic>genotype and CAD. Search terms included (ACE OR angiotensin converting enzyme) AND (gene OR polymorphism OR genetic variant) AND (myocardial infarction OR coronary artery disease OR coronary heart disease OR ischemic heart disease OR myocardial ischemia OR angina OR acute coronary syndrome). The retrieved studies were manually screened to assess their appropriateness for inclusion criteria. All references cited in the studies were also reviewed to identify additional published articles not indexed in the PubMed database. Case reports, editorials and review articles were excluded. The search was restricted to English-language articles of studies in humans.</p><p>The review included genetic association studies fulfilling the following inclusion criteria: (1) providing cases diagnosed with CAD or cohorts followed for CAD development, (2) using guideline-incorporated primary or secondary prevention measures for CAD [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B13">13</xref>], (3) investigating clinical outcomes of CAD (in primary or secondary prevention studies) or surrogate outcomes predicting clinical events in CAD patients, (4) providing information on genotype frequency for <italic>ACE I/D </italic>polymorphism or estimated genetic effects on response to treatment, and (5) using validated molecular methods for genotyping. Studies investigating susceptibility, progression, severity or survival, irrespective of treatment effect, were excluded from this review.</p></sec><sec><title>Data extraction</title><p>Two investigators (GK and EZ) independently extracted data. The extracted data included information about the study design characteristics, the assessed outcomes, the cohort characteristics, the intervention used and finally, the reported results. Disagreements were resolved through consensus. The quality of each study was also critically assessed by reporting a composite quality score to allow comparison among studies.</p></sec><sec><title>Data synthesis &#x02013; Statistical analysis</title><p>For each study, the statistical significance of the main findings for each treatment-outcome group was recorded or the respective odds ratios were calculated by the extracted genotypic frequencies.</p><p>In the case of studies with similar outcome definition criteria, identical intervention and available genotype frequency for each group, a meta-analysis was performed (see results). Three meta-analyses were performed to investigate the association between <italic>ACE I/D </italic>and the risk of restenosis after angioplasty for the allele contrast (<italic>D </italic>vs <italic>I</italic>), the recessive (<italic>DD </italic>vs. <italic>ID/II</italic>), the dominant (<italic>DD/ID </italic>vs. <italic>II</italic>), the additive (<italic>DD </italic>vs <italic>II</italic>) and the co-dominant (<italic>ID </italic>vs <italic>DD/II</italic>) models. We calculated the overall odds ratio (OR) with the corresponding 95% confidence interval (CI) using the fixed effects (FE) and random effects (RE; DerSimonian and Laird) models. Statistical heterogeneity across the various studies was tested with the use of <italic>Q</italic>-statistic [<xref ref-type="bibr" rid="B14">14</xref>]. A p value &#x0003c; 0.10 indicated a significant statistical heterogeneity across studies, allowing for the use of RE model.</p><p>A cumulative and recursive cumulative meta-analysis was also carried out [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. Cumulative and recursive cumulative meta-analyses provide a framework for updating a genetic effect from all studies and a measure of how much the genetic effect changes as evidence accumulates. Thus, cumulative meta-analysis indicates the trend in estimated risk effect and recursive cumulative meta-analysis indicates the stability in risk effect. In cumulative meta-analysis, studies were chronologically ordered by publication year, then, the pooled ORs were obtained at the end of each year, i.e. at each information step. In recursive cumulative meta-analysis, the relative change in pooled OR in each information step (pooled OR in next year/pooled OR in current year) was calculated. A differential magnitude of effect comparing large versus small studies for the allele contrast was verified using the Egger regression test [<xref ref-type="bibr" rid="B15">15</xref>].</p><p>In addition to the main (or overall) analysis which included all available data, a subgroup analysis for each "race" was also performed. 'Racial' descent was categorized into Caucasian descents (European and American whites), East Asian descents, mixed and populations of Turkish ancestry [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>The impact of study quality was assessed by performing subgroup analysis on studies with high quality and low quality components. The following parameters were considered as quality components: A. Internal validity criteria: homogeneous study group, blindness of genotyping, registration of loss to follow up, genotyping procedure (original procedure or use of Insertion-specific primers) [<xref ref-type="bibr" rid="B16">16</xref>], genotyping replication with another protocol, blindness and objectiveness of angiograms assessment. B. Data description and analysis criteria: data by gender provided, power calculations provided, overlapping with previous studies, description of cases recruitment procedure, assessment of gene-gene interactions, control for possible clinical and other modifiers between genotypes, control of co-interventions that bear on outcome for each genotype, availability of data, appropriate statistics-description and discussion of possible genetic effects. High quality studies were defined as studies that exceeded the median quality score [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>Analyses were performed using StatsDirect (StatsDirect Ltd), Compaq Visual Fortran90, and GLIM3.77.44&#x02013;50 [<xref ref-type="bibr" rid="B6">6</xref>].</p></sec></sec><sec><title>Results</title><sec><title>Eligible studies</title><p>The literature search identified 759 citations. All citations identified through the literature search were independently screened by two investigators (GK and EZ) according to the inclusion criteria. Two hundred fifty-nine articles were retrieved and evaluated against the same criteria. Data from 58 articles [<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B74">74</xref>] that investigated the association between <italic>ACE I/D </italic>polymorphism and response to treatment in CAD met the inclusion criteria, and were included in the review. Next, data from 28 studies [<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B29">29</xref>-<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B42">42</xref>-<xref ref-type="bibr" rid="B46">46</xref>,<xref ref-type="bibr" rid="B49">49</xref>] met the meta-analysis eligibility criteria and were included in the context of three meta-analyses. Figure <xref ref-type="fig" rid="F1">1</xref> presents a flow chart of retrieved studies and studies excluded, with specification of reasons.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Flow chart of retrieved studies and studies excluded, with specification of reasons</bold>.</p></caption><graphic xlink:href="1471-2350-10-50-1"/></fig></sec><sec><title>Summary statistics</title><p>Details from studies included in our database are provided in Table <xref ref-type="table" rid="T1">1</xref> and Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>. The interventions investigated were classified in two major categories: invasive (40 studies) and conservative (18 studies). The invasive treatments included coronary revascularization by percutaneous transluminal coronary angioplasty (PTCA) and coronary artery by-pass grafting (CABG). The conservative treatments included pharmacological interventions (16 studies) or cardiac rehabilitation procedures (two studies). The investigated outcomes were classified as clinical (11 studies) or surrogate (47 studies). The populations enrolled were of Caucasian (39 studies), East Asian (10 studies), mixed (six studies) or Turkish ancestry (three studies). Regarding study designs, our database included 44 cohort studies, eight randomized controlled trials, five cross-sectional and one retrospective study.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Summary information of studies included in the meta-analyses.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>First author, Year, Country [ref]</bold></td><td align="left"><bold>Study design, duration of FU</bold></td><td align="left"><bold>Cohort description [No of patients (M/F), Ethnicity, Mean Age (SD), inclusion criteria]</bold></td><td align="left"><bold>Restenosis definition criteria</bold></td><td align="left"><bold>Intervention</bold></td><td align="left"><bold>Gene-gene interaction assessed? (gene)</bold></td><td align="left"><bold>Quality score</bold></td></tr></thead><tbody><tr><td></td><td></td><td></td><td></td><td align="left"><bold>Balloon angioplasty</bold></td><td></td><td></td></tr><tr><td align="left">Volzke, 2000, Germany [<xref ref-type="bibr" rid="B17">17</xref>]</td><td align="left">cohort<break/>6 months</td><td align="left">511 (388/123), Caucasians, 60.6 (8.6), CAD patients undergoing elective PTCA of a previously untreated native coronary artery</td><td align="left">&#x0003e; 50% progression of the residual stenosis at FU</td><td align="left">PTCA-balloon</td><td align="left">No</td><td align="left">35</td></tr><tr><td align="left">Yoshida, 1999, Japan [<xref ref-type="bibr" rid="B18">18</xref>]</td><td align="left">cohort<break/>5.21 (3.9) years</td><td align="left">123 (nr), East Asians, 58.2 (10.2), MI patients undergoing PTCA discharged from hospital at the start of FU</td><td align="left">nr</td><td align="left">PTCA-balloon</td><td align="left">No</td><td align="left">30</td></tr><tr><td align="left">Kasi, 1996, Spain [<xref ref-type="bibr" rid="B19">19</xref>]</td><td align="left">cohort<break/>6 months</td><td align="left">69 (57/12), Caucasians, 58 (9.9), UA patients undergoing PTCA</td><td align="left">diameter stenosis &#x0003e; 50% at FU</td><td align="left">PTCA-balloon</td><td align="left">No</td><td align="left">27</td></tr><tr><td align="left">Kamitani, 1995, Japan [<xref ref-type="bibr" rid="B20">20</xref>]</td><td align="left">cohort<break/>6 months</td><td align="left">103 (103/00), East Asians, 52 (1), Primary PTCA for MI patients</td><td align="left">&#x0003e; 50% progression of the residual stenosis at FU</td><td align="left">PTCA-balloon</td><td align="left">No</td><td align="left">27</td></tr><tr><td align="left">Samani, 1995, UK [<xref ref-type="bibr" rid="B21">21</xref>]</td><td align="left">cohort<break/>4 months</td><td align="left">233 (194/39), nr, 56 (1), single-vessel PTCA in the Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) study</td><td align="left">&#x0003e; 50% progression of the residual stenosis at FU</td><td align="left">PTCA-balloon</td><td align="left">No</td><td align="left">34</td></tr><tr><td align="left">van Bockxmeer, 1995, Australia [<xref ref-type="bibr" rid="B22">22</xref>]</td><td align="left">cohort<break/>6 months</td><td align="left">207 (170/37), Caucasians, 57 (9), CAD patients undergoing elective PTCA</td><td align="left">&#x0003e; 50% progression of the residual stenosis at FU</td><td align="left">PTCA-balloon</td><td align="left">Yes (<italic>APOE</italic>)</td><td align="left">33</td></tr><tr><td align="left">Tsukada, 1997, Japan [<xref ref-type="bibr" rid="B23">23</xref>]</td><td align="left">cohort<break/>3 months</td><td align="left">96 (nr), East Asians, 60 (1.0), CAD patients undergoing elective PTCA</td><td align="left">diameter stenosis &#x0003e; 50% at FU</td><td align="left">PTCA-balloon</td><td align="left">No</td><td align="left">28</td></tr><tr><td align="left">Beohar, 1995, USA [<xref ref-type="bibr" rid="B24">24</xref>]</td><td align="left">cohort<break/>3 months</td><td align="left">89 (nr), Caucasians, 63.9 (10), CAD patients undergoing elective PTCA</td><td align="left">diameter stenosis &#x0003e; 50% at FU</td><td align="left">PTCA-balloon</td><td align="left">No</td><td align="left">24</td></tr><tr><td align="left">Zee, 2001, Spain [<xref ref-type="bibr" rid="B25">25</xref>]</td><td align="left">cohort<break/>6 months</td><td align="left">342 (305/37), Caucasians, 58.9 (9.6), CAD patients undergoing PTCA</td><td align="left">&#x0003e; 50% progression of the residual stenosis at FU</td><td align="left">PTCA-balloon</td><td align="left">No</td><td align="left">37</td></tr><tr><td align="left">Ohishi, 1993, Japan [<xref ref-type="bibr" rid="B26">26</xref>]</td><td align="left">cohort<break/>6 months</td><td align="left">82 (nr), East Asians, nr, MI patients undergoing primary PTCA</td><td align="left">&#x0003e; 50% progression of the residual stenosis at FU</td><td align="left">PTCA-balloon</td><td align="left">No</td><td align="left">23</td></tr><tr><td align="left">Hamon, 1998, France [<xref ref-type="bibr" rid="B37">37</xref>]</td><td align="left">cohort<break/>6 months</td><td align="left">271 (229/42), Caucasians, 60 (10), CAD patients undergoing PTCA</td><td align="left">diameter stenosis &#x0003e; 50% at FU</td><td align="left">PTCA-balloon</td><td align="left">Yes (<italic>AGT1R</italic>)</td><td align="left">34</td></tr><tr><td></td><td></td><td></td><td></td><td align="left"><bold>Angioplasty with stent deployment</bold></td><td></td><td></td></tr><tr><td align="left">Amant, 1997, France [<xref ref-type="bibr" rid="B30">30</xref>]</td><td align="left">cohort<break/>6 months</td><td align="left">146 (117/29), Caucasians, 60 (10) CAD patients undergoing PTCA</td><td align="left">diameter stenosis &#x0003e; 50% at FU</td><td align="left">PTCA-STENT</td><td align="left">No</td><td align="left">37</td></tr><tr><td align="left">Wijpkema, 2006, Netherlands [<xref ref-type="bibr" rid="B29">29</xref>]</td><td align="left">cohort<break/>9 months</td><td align="left">2888 (2050/838), Caucasians, 62 (11), CAD patients undergoing elective PTCA</td><td align="left">death from cardiac causes, MI attributable to target vessel and target vessel revascularization</td><td align="left">PTCA-STENT</td><td align="left">Yes (<italic>AGT, AGT1R, AGT2R, HMOX1</italic>)</td><td align="left">35</td></tr><tr><td align="left">Gomma, 2002, UK [<xref ref-type="bibr" rid="B31">31</xref>]</td><td align="left">cohort<break/>6 months</td><td align="left">205 (155/50), Caucasians, 59.4 (9.9), CAD patients undergoing PTCA</td><td align="left">diameter stenosis &#x0003e; 50% at FU</td><td align="left">PTCA-STENT</td><td align="left">No</td><td align="left">27</td></tr><tr><td align="left">Ruy, 2002, Korea [<xref ref-type="bibr" rid="B32">32</xref>]</td><td align="left">cohort<break/>6 months</td><td align="left">238 (178/60), East Asians, 59.5 (9.9), CAD patients undergoing PTCA</td><td align="left">diameter stenosis &#x0003e; 50% at FU</td><td align="left">PTCA-STENT</td><td align="left">Yes (<italic>CYP11B2, AGT</italic>)</td><td align="left">32</td></tr><tr><td align="left">Ribichini, 2004, Italy [<xref ref-type="bibr" rid="B33">33</xref>]</td><td align="left">cohort<break/>6 months</td><td align="left">897 (160/737), Caucasians, 61 (10), CAD patients undergoing PTCA</td><td align="left">diameter stenosis &#x0003e; 50% at FU</td><td align="left">PTCA-STENT</td><td align="left">No</td><td align="left">33</td></tr><tr><td align="left">Taniguchi, 2001, Japan [<xref ref-type="bibr" rid="B34">34</xref>]</td><td align="left">cohort<break/>6 months</td><td align="left">67 (50/17), East Asians, 65.2 (9.7), CAD patients undergoing PTCA</td><td align="left">&#x0003e; 50% progression of the residual stenosis at FU</td><td align="left">PTCA-STENT</td><td align="left">No</td><td align="left">23</td></tr><tr><td align="left">Koch, 2000, Germany [<xref ref-type="bibr" rid="B35">35</xref>]</td><td align="left">cohort<break/>1 year</td><td align="left">1850 (1458/392), Caucasians, 62.9 (10), CAD patients undergoing PTCA</td><td align="left">diameter stenosis &#x0003e; 50% at FU</td><td align="left">PTCA-STENT</td><td align="left">No</td><td align="left">40</td></tr><tr><td align="left">Gurlek, 2000, Turkey [<xref ref-type="bibr" rid="B36">36</xref>]</td><td align="left">cohort<break/>6 months</td><td align="left">132 (112/20), Turks, 53 (9), CAD patients undergoing PTCA</td><td align="left">diameter stenosis &#x0003e; 50% at FU</td><td align="left">PTCA-STENT</td><td align="left">No</td><td align="left">29</td></tr><tr><td align="left">Guneri, 2005, Turkey [<xref ref-type="bibr" rid="B43">43</xref>]</td><td align="left">cohort<break/>9 months (2.9)</td><td align="left">94 (59/35), Turks, 59.6 (9.9), CAD diabetic patients undergoing PTCA for stable angina pectoris</td><td align="left">diameter stenosis &#x0003e; 50% at FU</td><td align="left">PTCA-STENT</td><td align="left">No</td><td align="left">26</td></tr><tr><td></td><td></td><td></td><td></td><td align="left"><bold>Angioplasty with ACEi treatment</bold></td><td></td><td></td></tr><tr><td align="left">Ribichini, 2003, Italy [<xref ref-type="bibr" rid="B42">42</xref>]</td><td align="left">Cohort<break/>6.3 (2.5) months</td><td align="left">271 (nr), Caucasians, 61 (10), CAD patients undergoing PTCA</td><td align="left">diameter stenosis &#x0003e; 50% at FU</td><td align="left">PTCA-STENT + ACEi</td><td align="left">No</td><td align="left">35</td></tr><tr><td align="left">Okamura, 1999, Japan [<xref ref-type="bibr" rid="B44">44</xref>]</td><td align="left">cohort<break/>6 months</td><td align="left">97 (84/13), East Asians, 60 (2), CAD patients undergoing PTCA for stable angina pectoris</td><td align="left">diameter stenosis &#x0003e; 50% at FU</td><td align="left">PTCA-balloon + Imidapril 5 mg</td><td align="left">No</td><td align="left">29</td></tr><tr><td align="left">Okumura, 2002, Japan [<xref ref-type="bibr" rid="B45">45</xref>]</td><td align="left">cohort<break/>6 months</td><td align="left">92 (73/19), East Asians, 64.3 (8.9), CAD patients undergoing PTCA</td><td align="left">diameter stenosis &#x0003e; 50% at FU</td><td align="left">PTCA-STENT + Quinapril 18 mg</td><td align="left">No</td><td align="left">22</td></tr><tr><td align="left">Ferrari, 2002, multicenter (Europe) [<xref ref-type="bibr" rid="B46">46</xref>]</td><td align="left">cohort<break/>6 months</td><td align="left">154 (119/35), Caucasians, 61 (9.9), CAD patients undergoing PTCA</td><td align="left">&#x0003e; 50% progression of the residual stenosis at FU</td><td align="left">PTCA-STENT + ACEi</td><td align="left">No</td><td align="left">36</td></tr><tr><td align="left">Jorgensen, 2001, Netherlands [<xref ref-type="bibr" rid="B49">49</xref>]</td><td align="left">cohort<break/>6 months</td><td align="left">369 (293/76), Caucasians, 59 (43&#x02013;73), CAD patients undergoing PTCA for stable angina</td><td align="left">diameter stenosis &#x0003e; 50% at FU</td><td align="left">PTCA-STENT + ACEi</td><td align="left">No</td><td align="left">40</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: DCA: directional coronary atherectomy, FU: follow-up, UA: unstable angina, MI: myocardial infarction, RCT: randomized controlled trial, ACEi: angiotensin converting enzyme inhibitors, nr: non-reported</p></table-wrap-foot></table-wrap><p>We now present the results for each intervention in turn.</p></sec><sec><title>Invasive treatment strategies</title><sec><title>Percutaneous transluminal coronary angioplasty</title><p>Since the first reports of successful angioplasty of coronary atherosclerotic lesions, restenosis has been encountered as a significant limitation to the long-term efficacy of the procedure. Restenosis is an angiographically-defined outcome correlated with reduction in the quality of life and increase in the morbidity or even the mortality of patients [<xref ref-type="bibr" rid="B75">75</xref>]. Stenting has rapidly become the preferred method for PTCA, since it has distinct advantages over balloon angioplasty alone, including the reduction of the rate of restenosis from 50% to 20% [<xref ref-type="bibr" rid="B76">76</xref>].</p><p>Restenosis has been fitted into the standard multifactorial model of complex disease, although classical genetic epidemiological studies (twin or extended family studies) needed to establish the heritability of the phenotype are not practical and have not been conducted. Moreover, given the known importance of anatomical factors, procedural factors and diabetes in determining the risk of restenosis, any genetic effect seems <italic>a priori </italic>likely to be small [<xref ref-type="bibr" rid="B77">77</xref>]. Despite the lack of high biological plausibility, several studies have examined the risk of restenosis in association with <italic>ACE I/D </italic>polymorphism.</p><p>Overall 34 studies investigating restenosis were included (Table <xref ref-type="table" rid="T1">1</xref> and Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). Eleven studies used PTCA with balloon angioplasty alone (PTCA-balloon) [<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B37">37</xref>], 12 studies used PTCA with bare-metal stent deployment (PTCA-STENT) [<xref ref-type="bibr" rid="B29">29</xref>-<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B45">45</xref>,<xref ref-type="bibr" rid="B46">46</xref>,<xref ref-type="bibr" rid="B49">49</xref>], nine studies used PTCA and investigated the effect of concomitant administration of ACE inhibitors (ACEi) [<xref ref-type="bibr" rid="B42">42</xref>-<xref ref-type="bibr" rid="B50">50</xref>] and two studies used directional coronary atherectomy followed by PTCA [<xref ref-type="bibr" rid="B51">51</xref>,<xref ref-type="bibr" rid="B52">52</xref>]. The data from 28 studies [<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B29">29</xref>-<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B42">42</xref>-<xref ref-type="bibr" rid="B46">46</xref>,<xref ref-type="bibr" rid="B49">49</xref>] meeting the meta-analysis eligibility criteria were synthesized (Table <xref ref-type="table" rid="T1">1</xref>). Since the biological phenomena underlying restenosis after PTCA-balloon and PTCA-STENT are distinct (negative remodeling due to elastic recoil versus neointimal hyperplasia and inflammatory response, respectively) [<xref ref-type="bibr" rid="B78">78</xref>], separate meta-analyses for PTCA-balloon (11 studies included: [<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B37">37</xref>]) and PTCA-STENT (12 studies included: [<xref ref-type="bibr" rid="B29">29</xref>-<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B45">45</xref>,<xref ref-type="bibr" rid="B46">46</xref>,<xref ref-type="bibr" rid="B49">49</xref>]) were performed. Moreover, the interaction between PTCA and ACEi treatment was evaluated in the context of a third meta-analysis (five studies included: [<xref ref-type="bibr" rid="B42">42</xref>,<xref ref-type="bibr" rid="B44">44</xref>-<xref ref-type="bibr" rid="B46">46</xref>,<xref ref-type="bibr" rid="B49">49</xref>]). The findings of the studies not-included in the meta-analysis are presented in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>.</p></sec><sec><title>Main results, subgroup and sensitivity analyses</title><p>Table <xref ref-type="table" rid="T2">2</xref> and Figures <xref ref-type="fig" rid="F2">2a</xref>) and <xref ref-type="fig" rid="F2">2b</xref>) show the results for the association between <italic>ACE I/D </italic>gene polymorphism and the risk of restenosis after PTCA.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Odds ratios and heterogeneity results for the genetic contrasts of <italic>ACE I/D </italic>gene polymorphism for restenosis a) after PTCA-balloon, b) after PTCA-STENT, and c) after PTCA and treatment with ACE inhibitors.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">a)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></thead><tbody><tr><td align="left">Genetic contrast</td><td align="left">Population</td><td align="center">Studies</td><td align="center">Fixed effects<break/>OR(95%ci)</td><td align="center">Random effects<break/>OR(95%ci)</td><td align="center">I<sup>2</sup><break/>(%)</td><td align="center">p-value<break/>Q-test</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><italic>D </italic>vs.<italic>I</italic></td><td align="left">All</td><td align="center">11</td><td align="center">1.23(1.09&#x02013;1.38)</td><td align="center">1.34(1.09&#x02013;1.65)</td><td align="center">61</td><td align="center">&#x0003c; 0.01</td></tr><tr><td></td><td align="left">Caucasians</td><td align="center">7</td><td align="center">1.16(1.02&#x02013;1.31)</td><td align="center">1.16(1.02&#x02013;1.31)</td><td align="center">0</td><td align="center">0.58</td></tr><tr><td></td><td align="left">East Asians</td><td align="center">4</td><td align="center">1.75(1.29&#x02013;2.37)</td><td align="center">1.85(0.90&#x02013;3.83)</td><td align="center">81</td><td align="center">&#x0003c; 0.01</td></tr><tr><td></td><td align="left">High quality</td><td align="center">6</td><td align="center">1.13(0.99&#x02013;1.28)</td><td align="center">1.13(0.99&#x02013;1.28)</td><td align="center">0</td><td align="center">0.46</td></tr><tr><td></td><td align="left">Low quality</td><td align="center">5</td><td align="center">1.99(1.48&#x02013;2.69)</td><td align="center">1.95(1.21&#x02013;3.14)</td><td align="center">59</td><td align="center">0.05</td></tr><tr><td align="left"><italic>DD </italic>vs. (<italic>DI+II</italic>)</td><td align="left">All</td><td align="center">11</td><td align="center">1.30(1.09&#x02013;1.54)</td><td align="center">1.42(1.07&#x02013;1.91)</td><td align="center">52</td><td align="center">0.02</td></tr><tr><td></td><td align="left">Caucasians</td><td align="center">7</td><td align="center">1.20(1.00&#x02013;1.45)</td><td align="center">1.20(1.00&#x02013;1.45)</td><td align="center">0</td><td align="center">0.57</td></tr><tr><td></td><td align="left">East Asians</td><td align="center">4</td><td align="center">2.29(1.38&#x02013;3.80)</td><td align="center">1.88(0.65&#x02013;5.45)</td><td align="center">70</td><td align="center">0.02</td></tr><tr><td></td><td align="left">High quality</td><td align="center">6</td><td align="center">1.17(0.96&#x02013;1.41)</td><td align="center">1.19(0.96&#x02013;1.47)</td><td align="center">14</td><td align="center">0.32</td></tr><tr><td></td><td align="left">Low quality</td><td align="center">5</td><td align="center">2.24(1.45&#x02013;3.46)</td><td align="center">2.15(1.12&#x02013;4.10)</td><td align="center">50</td><td align="center">0.09</td></tr><tr><td align="left">(<italic>DD+ID</italic>) vs. <italic>II</italic></td><td align="left">All</td><td align="center">11</td><td align="center">1.32(1.08&#x02013;1.61)</td><td align="center">1.36(1.05&#x02013;1.76)</td><td align="center">27</td><td align="center">0.19</td></tr><tr><td></td><td align="left">Caucasians</td><td align="center">7</td><td align="center">1.23(0.98&#x02013;1.54)</td><td align="center">1.23(0.96&#x02013;1.57)</td><td align="center">10</td><td align="center">0.35</td></tr><tr><td></td><td align="left">East Asians</td><td align="center">4</td><td align="center">1.78(1.12&#x02013;2.82)</td><td align="center">1.87(0.98&#x02013;3.58)</td><td align="center">44</td><td align="center">0.15</td></tr><tr><td></td><td align="left">High quality</td><td align="center">6</td><td align="center">1.18(0.95&#x02013;1.48)</td><td align="center">1.18(0.92&#x02013;1.51)</td><td align="center">16</td><td align="center">0.31</td></tr><tr><td></td><td align="left">Low quality</td><td align="center">5</td><td align="center">2.27(1.38&#x02013;3.72)</td><td align="center">2.21(1.33&#x02013;3.66)</td><td align="center">0</td><td align="center">0.62</td></tr><tr><td align="left"><italic>DD </italic>vs.<italic>II</italic></td><td align="left">All</td><td align="center">11</td><td align="center">1.30(1.09&#x02013;1.54)</td><td align="center">1.42(1.07&#x02013;1.91)</td><td align="center">52</td><td align="center">0.02</td></tr><tr><td></td><td align="left">Caucasians</td><td align="center">7</td><td align="center">1.20(1.00&#x02013;1.45)</td><td align="center">1.20(1.00&#x02013;1.45)</td><td align="center">0</td><td align="center">0.57</td></tr><tr><td></td><td align="left">East Asians</td><td align="center">4</td><td align="center">2.29(1.38&#x02013;3.80)</td><td align="center">1.88(0.65&#x02013;5.45)</td><td align="center">70</td><td align="center">0.02</td></tr><tr><td></td><td align="left">High quality</td><td align="center">6</td><td align="center">1.17(0.96&#x02013;1.41)</td><td align="center">1.19(0.96&#x02013;1.47)</td><td align="center">14</td><td align="center">0.32</td></tr><tr><td></td><td align="left">Low quality</td><td align="center">5</td><td align="center">2.24(1.45&#x02013;3.46)</td><td align="center">2.15(1.12&#x02013;4.10)</td><td align="center">50</td><td align="center">0.09</td></tr><tr><td align="left"><italic>ID </italic>vs. (<italic>DD+II</italic>)</td><td align="left">All</td><td align="center">11</td><td align="center">0.96(0.82&#x02013;1.13)</td><td align="center">0.95(0.79&#x02013;1.15)</td><td align="center">14</td><td align="center">0.01</td></tr><tr><td></td><td align="left">Caucasians</td><td align="center">7</td><td align="center">0.97(0.81&#x02013;1.15)</td><td align="center">0.95(0.77&#x02013;1.18)</td><td align="center">21</td><td align="center">0.27</td></tr><tr><td></td><td align="left">East Asians</td><td align="center">4</td><td align="center">0.94(0.61&#x02013;1.45)</td><td align="center">0.93(0.55&#x02013;1.55)</td><td align="center">26</td><td align="center">0.26</td></tr><tr><td></td><td align="left">High quality</td><td align="center">6</td><td align="center">0.98(0.82&#x02013;1.17)</td><td align="center">0.97(0.78&#x02013;1.21)</td><td align="center">29</td><td align="center">0.22</td></tr><tr><td></td><td align="left">Low quality</td><td align="center">5</td><td align="center">0.87(0.57&#x02013;1.32)</td><td align="center">0.87(0.56&#x02013;1.36)</td><td align="center">7</td><td align="center">0.37</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left">b)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left">Genetic contrast</td><td align="center">Population</td><td align="center">Studies</td><td align="center">Fixed effects<break/>OR(95%ci)</td><td align="center">Random effects<break/>OR(95%ci)</td><td align="center">I<sup>2</sup><break/>(%)</td><td align="center">p-value<break/>Q-test</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><italic>D </italic>vs. <italic>I</italic></td><td align="left">All</td><td align="center">11</td><td align="center">1.03(0.94&#x02013;1.12)</td><td align="center">1.04(0.92&#x02013;1.16)</td><td align="center">25</td><td align="center">0.21</td></tr><tr><td></td><td align="left">Caucasians</td><td align="center">7</td><td align="center">1.01(0.92&#x02013;1.11)</td><td align="center">1.01(0.92&#x02013;1.11)</td><td align="center">0</td><td align="center">0.45</td></tr><tr><td></td><td align="left">East Asians</td><td align="center">2</td><td align="center">0.87(0.61&#x02013;1.26)</td><td align="center">0.88(0.61&#x02013;1.26)</td><td align="center">na</td><td align="center">0.61</td></tr><tr><td></td><td align="left">High quality</td><td align="center">6</td><td align="center">1.02(0.93&#x02013;1.12)</td><td align="center">1.02(0.93&#x02013;1.12)</td><td align="center">1</td><td align="center">0.41</td></tr><tr><td></td><td align="left">Low quality</td><td align="center">5</td><td align="center">1.05(0.84&#x02013;1.31)</td><td align="center">1.07(0.77&#x02013;1.49)</td><td align="center">52</td><td align="center">0.08</td></tr><tr><td align="left"><italic>DD </italic>vs. (<italic>DI+II</italic>)</td><td align="left">All</td><td align="center">11</td><td align="center">1.05(0.92&#x02013;1.21)</td><td align="center">1.07(0.92&#x02013;1.24)</td><td align="center">7</td><td align="center">0.38</td></tr><tr><td></td><td align="left">Caucasians</td><td align="center">7</td><td align="center">1.03(0.89&#x02013;1.20)</td><td align="center">1.05(0.88&#x02013;1.26)</td><td align="center">20</td><td align="center">0.28</td></tr><tr><td></td><td align="left">East Asians</td><td align="center">2</td><td align="center">1.18(0.61&#x02013;2.27)</td><td align="center">1.18(0.61&#x02013;2.28)</td><td align="center">na</td><td align="center">0.68</td></tr><tr><td></td><td align="left">High quality</td><td align="center">6</td><td align="center">1.04(0.89&#x02013;1.21)</td><td align="center">1.07(0.87&#x02013;1.32)</td><td align="center">32</td><td align="center">0.20</td></tr><tr><td></td><td align="left">Low quality</td><td align="center">5</td><td align="center">1.16(0.82&#x02013;1.65)</td><td align="center">1.17(0.82&#x02013;1.66)</td><td align="center">0</td><td align="center">0.56</td></tr><tr><td align="left">(<italic>DD+ID</italic>) vs. <italic>II</italic></td><td align="left">All</td><td align="center">12</td><td align="center">1.01(0.87&#x02013;1.16)</td><td align="center">0.96(0.79&#x02013;1.18)</td><td align="center">30</td><td align="center">0.16</td></tr><tr><td></td><td align="left">Caucasians</td><td align="center">7</td><td align="center">1.00(0.86&#x02013;1.17)</td><td align="center">1.00(0.86&#x02013;1.16)</td><td align="center">0</td><td align="center">0.45</td></tr><tr><td></td><td align="left">East Asians</td><td align="center">3</td><td align="center">0.67(0.42&#x02013;1.06)</td><td align="center">0.67(0.42&#x02013;1.07)</td><td align="center">0</td><td align="center">0.88</td></tr><tr><td></td><td align="left">High quality</td><td align="center">6</td><td align="center">1.02(0.88&#x02013;1.19)</td><td align="center">1.02(0.87&#x02013;1.19)</td><td align="center">0</td><td align="center">0.43</td></tr><tr><td></td><td align="left">Low quality</td><td align="center">6</td><td align="center">0.93(0.67&#x02013;1.30)</td><td align="center">0.99(0.58&#x02013;1.68)</td><td align="center">51</td><td align="center">0.07</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left">c)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left">Genetic contrast</td><td align="center">Population</td><td align="center">Studies</td><td align="center">Fixed effects<break/>OR(95%ci)</td><td align="center">Random effects<break/>OR(95%ci)</td><td align="center">I<sup>2</sup><break/>(%)</td><td align="center">p-value<break/>Q-test</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><italic>D </italic>vs. <italic>I</italic></td><td align="left">Whites</td><td align="center">3</td><td align="center">1.10(0.81&#x02013;1.48)</td><td align="center">1.10(0.81&#x02013;1.48)</td><td align="center">0</td><td align="center">0.42</td></tr><tr><td align="left"><italic>DD </italic>vs. (<italic>DI+II</italic>)</td><td align="left">Whites</td><td align="center">3</td><td align="center">1.50(0.97&#x02013;2.28)</td><td align="center">1.74(0.78&#x02013;3.87)</td><td align="center">42.8</td><td align="center">0.17</td></tr><tr><td align="left">(<italic>DD+ID</italic>) vs. <italic>II</italic></td><td align="left">All</td><td align="center">5</td><td align="center">0.85(0.52&#x02013;1.38)</td><td align="center">0.86(0.43&#x02013;1.74)</td><td align="center">31.2</td><td align="center">0.21</td></tr><tr><td></td><td align="left">Whites</td><td align="center">3</td><td align="center">0.71(0.41&#x02013;1.22)</td><td align="center">0.70(0.41&#x02013;1.22)</td><td align="center">0</td><td align="center">0.93</td></tr><tr><td></td><td align="left">East Asians</td><td align="center">2</td><td align="center">1.64(0.57&#x02013;4.74)</td><td align="center">1.22(0.09&#x02013;16.61)</td><td align="center">na</td><td align="center">0.05</td></tr></tbody></table></table-wrap><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Random effects (RE) odds ratio (OR) estimates with the corresponding 95% confidence interval (CI) of the allele contrast (<italic>ACE D </italic>vs. <italic>I</italic>) for restenosis a) after PTCA-balloon, and b) after PTCA-STENT</bold>. The OR estimate of each study is marked with a solid black square. The size of the square represents the weight that the corresponding study exerts in the meta-analysis. The confidence intervals of pooled estimates are displayed as a horizontal line through the diamond. The horizontal axis is plotted on a log scale.</p></caption><graphic xlink:href="1471-2350-10-50-2"/></fig><p>All studies investigating restenosis after PTCA-balloon were included in the meta-analysis. The main analysis for investigating the association between allele <italic>D </italic>and the risk of restenosis after PTCA-balloon relative to the allele <italic>I</italic>, revealed significant heterogeneity (p &#x0003c; 0.01) among studies and, the random effects pooled OR was significant (RE OR 1.34(1.09&#x02013;1.65)). The recessive and dominant models also showed significant association (RE OR = 1.42(1.07&#x02013;1.91) and RE OR = 1.36(1.05&#x02013;1.76), respectively). The additive model produced significant association (RE OR = 1.42(1.07&#x02013;1.91)) and the co-dominant model non-significant association (RE OR = 0.95(0.79&#x02013;1.15)) as it was anticipated. Thus, <italic>ACE I/D </italic>polymorphism contributes to risk of restenosis under an additive model. In subgroup analysis by "race", Caucasians showed lack of significant heterogeneity (pQ = 0.58) and a marginal significance for the allele contrast (FE OR = 1.16(1.02&#x02013;1.31)) whereas East Asians revealed significant heterogeneity among studies (pQ &#x0003c; 0.01) and non-significant association (RE OR = 1.85(0.90&#x02013;3.83)).</p><p>On the contrary, in the meta-analyses investigating the risk of restenosis after PTCA-STENT or after PTCA and treatment with ACEi, there was non-significant heterogeneity among studies (pQ &#x0003e; 0.10) and the association was non-significant overall, for Whites and East Asians, under any genetic model.</p><p>Potential Bias. The cumulative meta-analysis of the allelic contrast for restenosis after PTCA-balloon showed a trend of association as information accumulates (Figure <xref ref-type="fig" rid="F3">3</xref>). In recursive cumulative meta-analysis, the relative change in RE OR stabilized after 1996/1995 indicating that there is sufficient evidence for supporting an association (Figure <xref ref-type="fig" rid="F4">4a</xref>). In contrast, analysis for restenosis after PTCA-STENT showed that the association remained non-significant for the whole period (Figure <xref ref-type="fig" rid="F3">3</xref>). In the recursive cumulative meta-analysis, the relative change in RE OR did not stabilize in a specific OR indicating the need of more evidence for investigating the association (Figure <xref ref-type="fig" rid="F4">4b</xref>). The subgroup analysis for study quality showed lack of significant heterogeneity (pQ = 0.46) and produced non-significant association (FE OR = 1.13(0.99&#x02013;1.28)) in the case of high-quality studies for PTCA-balloon. In contrast, low quality studies showed significant heterogeneity (pQ = 0.05) and significant association (RE OR = 1.99(1.48&#x02013;2.69)) (Table <xref ref-type="table" rid="T2">2</xref>). For PTCA-STENT studies, the subgroup analysis by quality did not reveal any significant associations, though significant heterogeneity across low quality studies was observed (pQ = 0.08). The Egger test for the allele contrast indicated that there is differential magnitude of effect in large versus small studies (p &#x0003c; 0.08).</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Cumulative meta-analysis of the allele contrast (<italic>ACE D </italic>vs. <italic>I</italic>) for restenosis a) after PTCA-balloon, and b) after PTCA-STENT</bold>. The random effects pooled odds ratio (OR) with the corresponding 95% confidence interval (CI) at the end of each year-information step is shown.</p></caption><graphic xlink:href="1471-2350-10-50-3"/></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>Recursive cumulative meta-analysis of the allele contrast (<italic>ACE D </italic>vs. <italic>I</italic>) for restenosis a) after PTCA-balloon, and b) after PTCA-STENT</bold>. The relative change in random effects pooled odds ratio (OR) in each information step (OR in next year/OR in current year) for the allele contrast is shown.</p></caption><graphic xlink:href="1471-2350-10-50-4"/></fig></sec><sec><title>Coronary artery by-pass grafting</title><p>Two small-scale studies [<xref ref-type="bibr" rid="B53">53</xref>,<xref ref-type="bibr" rid="B54">54</xref>] investigated the risk of atherosclerotic degeneration in venous grafts in association with the <italic>ACE I/D </italic>polymorphism, but the reported results are discrepant (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). In a European cohort of CAD patients treated with CABG, the <italic>ACE </italic>genotype was an independent predictor of total and cardiac mortality in two-year follow up, explaining 17.7% of cardiac events, although a relationship of <italic>I/D </italic>polymorphism with graft atherosclerosis was not investigated [<xref ref-type="bibr" rid="B55">55</xref>].</p></sec></sec><sec><title>Conservative treatment strategies</title><p>The results are summarized in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>.</p><sec><title>Anti-hypertensive therapy</title><p>Two primary prevention trials of CAD assessed the effect of <italic>ACE I/D </italic>on anti-hypertensive therapy and reported non-significant results overall [<xref ref-type="bibr" rid="B57">57</xref>,<xref ref-type="bibr" rid="B58">58</xref>]. The GenHAT study [<xref ref-type="bibr" rid="B57">57</xref>] found no differences for the primary endpoint of fatal CAD and nonfatal MI across gene-drug strata. <italic>ACE I/D </italic>polymorphism was found to be significant only in the subgroup of women treated with lisinopril. In the PROGRESS study that enrolled patients with history of cerebrovascular disease, there were no <italic>ACE</italic>-genotype specific benefits of perindopril administration on the outcome of fatal CAD and nonfatal MI [<xref ref-type="bibr" rid="B58">58</xref>]. A retrospective study by Marciante et al. [<xref ref-type="bibr" rid="B59">59</xref>] was the first study to examine the role of haplotypic variation in <italic>ACE </italic>gene on primary prevention of MI. None of the examined <italic>ACE </italic>haplotypes (capturing the <italic>I/D </italic>polymorphism) was associated with the risk of MI in pharmacologically treated hypertensive patients.</p><p>The effect of <italic>ACE I/D </italic>polymorphism and ACEi treatment on surrogate CAD outcomes was investigated by eight studies [<xref ref-type="bibr" rid="B60">60</xref>-<xref ref-type="bibr" rid="B67">67</xref>] (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). The reported results are diverse and inconsistent, derived mainly from underpowered or non-randomised studies.</p></sec><sec><title>Lipid lowering treatment</title><p>Regarding clinical outcomes, three randomized trials failed to show any significant <italic>ACE </italic>genotype-statin treatment interactions in primary [<xref ref-type="bibr" rid="B68">68</xref>] or secondary prevention [<xref ref-type="bibr" rid="B70">70</xref>,<xref ref-type="bibr" rid="B71">71</xref>] of CAD (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). Additionally, in the observational Rotterdam study, non-significant associations were reported overall, although a significant interaction between the <italic>ACE </italic>gene and the use of statins was observed in male participants [<xref ref-type="bibr" rid="B69">69</xref>]. Regarding the angiographic assessment of CAD progression or regression after statin treatment, the <italic>ACE I/D </italic>genotype was found to be a major modifier, with <italic>DD </italic>patients being more likely to have definite regression of coronary lesions, consistent with a greater reduction in low density lipoprotein cholesterol levels [<xref ref-type="bibr" rid="B71">71</xref>].</p></sec><sec><title>Cardiac rehabilitation</title><p>Two studies examined the role of <italic>ACE I/D </italic>polymorphism in modifying the response of physical training in aerobic and exercise capacity in CAD patients. Defoor et al. [<xref ref-type="bibr" rid="B73">73</xref>] found a greater beneficial effect in patients with <italic>II </italic>genotype than in <italic>D </italic>allele carriers, while Iwanaga et al. [<xref ref-type="bibr" rid="B74">74</xref>] reported no significant findings in their smaller study.</p></sec></sec></sec><sec><title>Discussion</title><p>In this review, we have explored a large and varied literature and have found a wide range of quality of evidence. The studies reviewed offer inconclusive and in many cases contradictory results. The most widely investigated outcome was the restenosis post-PTCA. We conducted meta-analyses to shed some light on the contradictory results, as well as to decrease the uncertainty of the effect size of estimated risk.</p><p>The risk of restenosis following PTCA-balloon was consistent for the allele contrast, the recessive, the dominant and additive models, though the results showed significant heterogeneity. Heterogeneity may result from differences in sample selection (e.g., in age-at-onset, gender, or diagnostic criteria), in genotyping methodology (two different genotyping procedures were used), or may be due to real differences in populations (e.g., 'racial' descent) or due to interactions with other unknown risk factors [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>The results of the meta-analysis were affected by population origin. Caucasians showed significance under the allele contrast whereas East Asians produced non-significant results. The lower frequency of the <italic>DD </italic>genotype in East Asian populations, coupled with the small sample size in most studies, imply that any negative conclusion could be due to low statistical power. True race-specific genetic effects could explain this pattern of results, since functional analyses of variation in <italic>ACE </italic>gene have indicated that different loci control ACE levels in particular 'racial' groups [<xref ref-type="bibr" rid="B79">79</xref>]. Nevertheless, any inconsistencies in risk effects of <italic>ACE I/D </italic>on restenosis between Caucasian and East Asians might be also due to race-related anatomical differences of coronary arteries, since a smaller total vessel diameter has been described for Asian populations [<xref ref-type="bibr" rid="B80">80</xref>].</p><p>The need for cumulative and recursive cumulative meta-analyses has already been highlighted [<xref ref-type="bibr" rid="B6">6</xref>]. The stability in the relative changes in ORs indicates that there is enough evidence to draw safe conclusions about the modifying effect of <italic>ACE I/D </italic>polymorphism in restenosis post-PTCA. However, the results of the subgroup analysis by quality [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B81">81</xref>] make the robustness of the main analysis questionable.</p><p>Regarding the <italic>ACE I/D </italic>polymorphism and the risk of restenosis after PTCA-STENT or after PTCA and treatment with ACEi, there was non-significant heterogeneity among studies and the association was non-significant overall and for all examined subgroups, under any genetic model. Despite higher biological plausibility in the context of the PTCA-STENT intervention (the renin-angiotensin-aldosterone system is considered to be more implicated in the inflammatory processes of neointimal growth underlying post-PTCA-STENT restenosis, rather than in elastic recoil remodeling following PTCA-balloon) [<xref ref-type="bibr" rid="B78">78</xref>], the <italic>ACE </italic>polymorphism was not associated with higher restenosis risk. The instability of the RE OR in the recursive cumulative meta-analysis indicated the need of more evidence to draw safer conclusions.</p><p>Our analysis showed a differential magnitude of effect in large versus small studies. Previous meta-analyses had already highlighted that the pooled estimate based on published literature, which favoured an association, was probably distorted by publication bias toward positive results [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. However, our analysis was based on a substantially larger number of studies (including a total of 9945 patients vs 4631 and 3150 patients that were used in previous meta-analyses [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>], respectively), which allowed investigation of <italic>ACE I/D </italic>and angioplasty interaction in the context of three clinically relevant distinct meta-analyses. The <italic>ACE I/D </italic>polymorphism was associated only with restenosis post-PTCA-balloon and contrary to previous findings [<xref ref-type="bibr" rid="B8">8</xref>], the results for this association showed significant heterogeneity. Our subgroup analysis identified ethnicity as a potential factor contributing to heterogeneity and highlighted the effect of study quality on summary estimates, which had not been previously addressed. Additionally, the studies on the <italic>ACE I/D </italic>and restenosis following PTCA-STENT were not significantly heterogeneous, contradicting previous findings [<xref ref-type="bibr" rid="B8">8</xref>], although the instability of the RE OR in the recursive cumulative meta-analysis indicated that this potential association remains an unresolved issue.</p><p>All of the analyzed studies in the meta-analysis for PTCA-STENT involved bare metal stents. Given the near-universal adoption of stenting as the default strategy for PTCA, the <italic>ACE I/D </italic>polymorphism can not be considered as a reliable genetic marker of restenosis after PTCA. Nevertheless, in the era of drug-eluting stents [<xref ref-type="bibr" rid="B82">82</xref>], late stent thrombosis emerges as a clinically important outcome that probably merits at least equivalent attention to restenosis in the design of future studies.</p><p>The treatment modalities in which <italic>ACE </italic>gene has been investigated as a potential modifier gene are diverse and not linked by common molecular mechanisms, thus questioning the biological rationale underlying the selection of this candidate gene. The discrepancy of the observed results regarding the clinical and surrogate outcomes of the other interventions (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>) could be due to a series of factors, including heterogeneity of enrolled cases, outcome definition variability, genotyping errors [<xref ref-type="bibr" rid="B16">16</xref>], limited statistical power, different study designs and variable interventions (in terms of type, dose, duration or timing). Downgrading the potential significance of <italic>ACE I/D </italic>polymorphism in the pharmacogenetics of CAD, none of the six studies enrolling more than 1,000 individuals [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B57">57</xref>,<xref ref-type="bibr" rid="B58">58</xref>,<xref ref-type="bibr" rid="B68">68</xref>] reported significant results on its respective outcomes.</p><p>Large, prospective studies with similar study designs, detailed clinical records, standardised outcome definitions, limited variability in subjects enrolled and interventions used, are needed. Moreover, if researchers can make their data on individual patients readily available, adjusted estimates for the effects of modifiers (such as age or gender) can also be analyzed.</p><p>Since the <italic>ACE I/D </italic>polymorphism is intronic, it is unlikely that it is functional. Despite considerable effort, the precise location of the functional polymorphism, or polymorphisms, is still unknown [<xref ref-type="bibr" rid="B83">83</xref>]. Future studies utilizing the HapMap tagging SNPs data, could provide useful insights, regarding the disease-associated gene haplotypes. So far, only one study [<xref ref-type="bibr" rid="B59">59</xref>] used the haplotype approach reporting negative results. In addition, the effect of epistatic loci interacting with <italic>ACE I/D </italic>remains a poorly investigated issue [<xref ref-type="bibr" rid="B7">7</xref>]. Elucidating the modifying effect of the renin-angiotensin-aldosterone system on response to treatment to CAD would demand a multigene haplotype approach searching for variation throughout this pathophysiological pathway [<xref ref-type="bibr" rid="B84">84</xref>]. With the advent of 'agnostic' genome-wide association studies, novel variants of unprecedented biological suspicion can be unravelled by properly designed and well-powered pharmacogenomic studies [<xref ref-type="bibr" rid="B85">85</xref>].</p><p>Cost-effectiveness analyses are crucial inputs in pharmacogenetic studies prior implementation of genetic tests in clinical practice [<xref ref-type="bibr" rid="B86">86</xref>]. Despite some promising initial pharmacoeconomic investigations [<xref ref-type="bibr" rid="B87">87</xref>], the <italic>ACE I/D </italic>genotype and treatment interactions in CAD are not reproducible and convincing enough to justify clinical implementation any time soon.</p></sec><sec><title>Conclusion</title><p>Many studies have tried to characterize the effects of <italic>ACE I/D </italic>polymorphism on the response to treatment in CAD, in the context of both interventional and conservative therapeutic options for clinical and surrogate endpoints. However, the reported results so far are discrepant and inconsistent. In view of available evidence, genetic testing of <italic>ACE I/D </italic>polymorphism prior to clinical decision making is not currently justified. The relation between <italic>ACE </italic>genetic variation and response to treatment in CAD remains an unresolved issue. The results of long-term and properly designed prospective studies hold the promise for pharmacogenetically tailored therapy in CAD.</p></sec><sec><title>Abbreviations</title><p>All abbreviations are defined in the text.</p></sec><sec><title>Competing interests</title><p>Georgios Kitsios is Pfizer-Tufts Medical Center Research Fellow in Clinical Research.</p></sec><sec><title>Authors' contributions</title><p>GK and EZ designed the study and drafted the manuscript. GK and EZ extracted the data and EZ analyzed the data. Both authors had equal contribution to the revised manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/10/50/prepub"/></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>Summary information of studies not included in the meta-analyses</bold>. The data provided represent the extracted information from studies not considered in the meta-analyses.</p></caption><media xlink:href="1471-2350-10-50-S1.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>Scientific support for this project was provided through the Tufts Clinical and Translational Science Institute (Tufts CTSI) under funding from the National Institute of Health/National Center for Research Resources (UL1 RR025752). Points of view or opinions in this paper are those of the authors and do not necessarily represent the official position or policies of the Tufts CTSI.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnett</surname><given-names>DK</given-names></name><name><surname>Baird</surname><given-names>AE</given-names></name><name><surname>Barkley</surname><given-names>RA</given-names></name><name><surname>Basson</surname><given-names>CT</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Ganesh</surname><given-names>SK</given-names></name><name><surname>Herrington</surname><given-names>DM</given-names></name><name><surname>Hong</surname><given-names>Y</given-names></name><name><surname>Jaquish</surname><given-names>C</given-names></name><name><surname>McDermott</surname><given-names>DA</given-names></name><name><surname>O'Donnell</surname><given-names>CJ</given-names></name><collab>American Heart Association Council on Epidemiology and Prevention; American Heart Association Stroke Council; Functional Genomics and Translational Biology Interdisciplinary Working Group</collab></person-group><article-title>Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group</article-title><source>Circulation</source><year>2007</year><volume>115</volume><fpage>2878</fpage><lpage>2901</lpage><pub-id pub-id-type="pmid">17515457</pub-id><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.183679</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zintzaras</surname><given-names>E</given-names></name><name><surname>Kitsios</surname><given-names>G</given-names></name></person-group><article-title>Identification of chromosomal regions linked to premature myocardial infarction: a meta-analysis of whole-genome searches</article-title><source>J Hum Genet</source><year>2006</year><volume>51</volume><fpage>1015</fpage><lpage>1021</lpage><pub-id pub-id-type="pmid">17024316</pub-id><pub-id pub-id-type="doi">10.1007/s10038-006-0053-x</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Damani</surname><given-names>SB</given-names></name><name><surname>Topol</surname><given-names>EJ</given-names></name></person-group><article-title>Future use of genomics in coronary artery disease</article-title><source>J Am Coll Cardiol</source><year>2007</year><volume>50</volume><fpage>1933</fpage><lpage>1940</lpage><pub-id pub-id-type="pmid">17996556</pub-id><pub-id pub-id-type="doi">10.1016/j.jacc.2007.07.062</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Unal</surname><given-names>B</given-names></name><name><surname>Critchley</surname><given-names>JA</given-names></name><name><surname>Capewell</surname><given-names>S</given-names></name></person-group><article-title>Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000</article-title><source>Circulation</source><year>2004</year><volume>109</volume><fpage>1101</fpage><lpage>1107</lpage><pub-id pub-id-type="pmid">14993137</pub-id><pub-id pub-id-type="doi">10.1161/01.CIR.0000118498.35499.B2</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>JA</given-names></name><name><surname>Cavallari</surname><given-names>LH</given-names></name></person-group><article-title>Cardiovascular pharmacogenomics</article-title><source>Exp Physiol</source><year>2005</year><volume>90</volume><fpage>283</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">15778411</pub-id><pub-id pub-id-type="doi">10.1113/expphysiol.2004.028506</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zintzaras</surname><given-names>E</given-names></name><name><surname>Raman</surname><given-names>G</given-names></name><name><surname>Kitsios</surname><given-names>G</given-names></name><name><surname>Lau</surname><given-names>J</given-names></name></person-group><article-title>Angiotensin-converting enzyme insertion/deletion gene polymorphic variant as a marker of coronary artery disease: a meta-analysis</article-title><source>Arch Intern Med</source><year>2008</year><volume>168</volume><fpage>1077</fpage><lpage>1089</lpage><pub-id pub-id-type="pmid">18504336</pub-id><pub-id pub-id-type="doi">10.1001/archinte.168.10.1077</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonnici</surname><given-names>F</given-names></name><name><surname>Keavney</surname><given-names>B</given-names></name><name><surname>Collins</surname><given-names>R</given-names></name><name><surname>Danesh</surname><given-names>J</given-names></name></person-group><article-title>Angiotensin converting enzyme insertion or deletion polymorphism and coronary restenosis: meta-analysis of 16 studies</article-title><source>BMJ</source><year>2002</year><volume>325</volume><fpage>517</fpage><lpage>520</lpage><pub-id pub-id-type="pmid">12217990</pub-id><pub-id pub-id-type="doi">10.1136/bmj.325.7363.517</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agema</surname><given-names>WR</given-names></name><name><surname>Jukema</surname><given-names>JW</given-names></name><name><surname>Zwinderman</surname><given-names>AH</given-names></name><name><surname>Wall</surname><given-names>EE van der</given-names></name></person-group><article-title>A meta-analysis of the angiotensin-converting enzyme gene polymorphism and restenosis after percutaneous transluminal coronary revascularization: evidence for publication bias</article-title><source>Am Heart J</source><year>2002</year><volume>144</volume><fpage>760</fpage><lpage>768</lpage><pub-id pub-id-type="pmid">12422143</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Danser</surname><given-names>AH</given-names></name><name><surname>Schalekamp</surname><given-names>MA</given-names></name><name><surname>Bax</surname><given-names>WA</given-names></name><name><surname>Brink</surname><given-names>AM van den</given-names></name><name><surname>Saxena</surname><given-names>PR</given-names></name><name><surname>Riegger</surname><given-names>GA</given-names></name><name><surname>Schunkert</surname><given-names>H</given-names></name></person-group><article-title>Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism</article-title><source>Circulation</source><year>1995</year><volume>92</volume><fpage>1387</fpage><lpage>1388</lpage><pub-id pub-id-type="pmid">7664416</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>JL</given-names></name><name><surname>Adams</surname><given-names>CD</given-names></name><name><surname>Antman</surname><given-names>EM</given-names></name><name><surname>Bridges</surname><given-names>CR</given-names></name><name><surname>Califf</surname><given-names>RM</given-names></name><name><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></name><name><surname>Chavey</surname><given-names>WE</given-names><suffix>2nd</suffix></name><name><surname>Fesmire</surname><given-names>FM</given-names></name><name><surname>Hochman</surname><given-names>JS</given-names></name><name><surname>Levin</surname><given-names>TN</given-names></name><name><surname>Lincoff</surname><given-names>AM</given-names></name><name><surname>Peterson</surname><given-names>ED</given-names></name><name><surname>Theroux</surname><given-names>P</given-names></name><name><surname>Wenger</surname><given-names>NK</given-names></name><name><surname>Wright</surname><given-names>RS</given-names></name><name><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></name><name><surname>Jacobs</surname><given-names>AK</given-names></name><name><surname>Adams</surname><given-names>CD</given-names></name><name><surname>Anderson</surname><given-names>JL</given-names></name><name><surname>Antman</surname><given-names>EM</given-names></name><name><surname>Halperin</surname><given-names>JL</given-names></name><name><surname>Hunt</surname><given-names>SA</given-names></name><name><surname>Krumholz</surname><given-names>HM</given-names></name><name><surname>Kushner</surname><given-names>FG</given-names></name><name><surname>Lytle</surname><given-names>BW</given-names></name><name><surname>Nishimura</surname><given-names>R</given-names></name><name><surname>Ornato</surname><given-names>JP</given-names></name><name><surname>Page</surname><given-names>RL</given-names></name><name><surname>Riegel</surname><given-names>B</given-names></name><collab>American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine</collab></person-group><article-title>ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine</article-title><source>Circulation</source><year>2007</year><volume>116</volume><fpage>e148</fpage><lpage>e304</lpage><pub-id pub-id-type="pmid">17679616</pub-id><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.737312</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Antman</surname><given-names>EM</given-names></name><name><surname>Hand</surname><given-names>M</given-names></name><name><surname>Armstrong</surname><given-names>PW</given-names></name><name><surname>Bates</surname><given-names>ER</given-names></name><name><surname>Green</surname><given-names>LA</given-names></name><name><surname>Halasyamani</surname><given-names>LK</given-names></name><name><surname>Hochman</surname><given-names>JS</given-names></name><name><surname>Krumholz</surname><given-names>HM</given-names></name><name><surname>Lamas</surname><given-names>GA</given-names></name><name><surname>Mullany</surname><given-names>CJ</given-names></name><name><surname>Pearle</surname><given-names>DL</given-names></name><name><surname>Sloan</surname><given-names>MA</given-names></name><name><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></name><collab>2004 Writing Committee Members</collab><name><surname>Anbe</surname><given-names>DT</given-names></name><name><surname>Kushner</surname><given-names>FG</given-names></name><name><surname>Ornato</surname><given-names>JP</given-names></name><name><surname>Jacobs</surname><given-names>AK</given-names></name><name><surname>Adams</surname><given-names>CD</given-names></name><name><surname>Anderson</surname><given-names>JL</given-names></name><name><surname>Buller</surname><given-names>CE</given-names></name><name><surname>Creager</surname><given-names>MA</given-names></name><name><surname>Ettinger</surname><given-names>SM</given-names></name><name><surname>Halperin</surname><given-names>JL</given-names></name><name><surname>Hunt</surname><given-names>SA</given-names></name><name><surname>Lytle</surname><given-names>BW</given-names></name><name><surname>Nishimura</surname><given-names>R</given-names></name><name><surname>Page</surname><given-names>RL</given-names></name><name><surname>Riegel</surname><given-names>B</given-names></name><name><surname>Tarkington</surname><given-names>LG</given-names></name><name><surname>Yancy</surname><given-names>CW</given-names></name></person-group><article-title>2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee</article-title><source>Circulation</source><year>2008</year><volume>117</volume><fpage>296</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">18071078</pub-id><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.188209</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fraker</surname><given-names>TD</given-names><suffix>Jr</suffix></name><name><surname>Fihn</surname><given-names>SD</given-names></name><name><surname>Gibbons</surname><given-names>RJ</given-names></name><name><surname>Abrams</surname><given-names>J</given-names></name><name><surname>Chatterjee</surname><given-names>K</given-names></name><name><surname>Daley</surname><given-names>J</given-names></name><name><surname>Deedwania</surname><given-names>PC</given-names></name><name><surname>Douglas</surname><given-names>JS</given-names></name><name><surname>Ferguson</surname><given-names>TB</given-names><suffix>Jr</suffix></name><name><surname>Fihn</surname><given-names>SD</given-names></name><name><surname>Fraker</surname><given-names>TD</given-names><suffix>Jr</suffix></name><name><surname>Gardin</surname><given-names>JM</given-names></name><name><surname>O'Rourke</surname><given-names>RA</given-names></name><name><surname>Williams</surname><given-names>SV</given-names></name><name><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></name><name><surname>Jacobs</surname><given-names>AK</given-names></name><name><surname>Adams</surname><given-names>CD</given-names></name><name><surname>Anderson</surname><given-names>JL</given-names></name><name><surname>Buller</surname><given-names>CE</given-names></name><name><surname>Creager</surname><given-names>MA</given-names></name><name><surname>Ettinger</surname><given-names>SM</given-names></name><name><surname>Halperin</surname><given-names>JL</given-names></name><name><surname>Hunt</surname><given-names>SA</given-names></name><name><surname>Krumholz</surname><given-names>HM</given-names></name><name><surname>Kushner</surname><given-names>FG</given-names></name><name><surname>Lytle</surname><given-names>BW</given-names></name><name><surname>Nishimura</surname><given-names>R</given-names></name><name><surname>Page</surname><given-names>RL</given-names></name><name><surname>Riegel</surname><given-names>B</given-names></name><name><surname>Tarkington</surname><given-names>LG</given-names></name><name><surname>Yancy</surname><given-names>CW</given-names></name><collab>American College of Cardiology; American Heart Association; American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group</collab></person-group><article-title>2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina</article-title><source>Circulation</source><year>2007</year><volume>116</volume><fpage>2762</fpage><lpage>2772</lpage><pub-id pub-id-type="pmid">17998462</pub-id><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.187930</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><collab>Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts</collab><name><surname>Graham</surname><given-names>I</given-names></name><name><surname>Atar</surname><given-names>D</given-names></name><name><surname>Borch-Johnsen</surname><given-names>K</given-names></name><name><surname>Boysen</surname><given-names>G</given-names></name><name><surname>Burell</surname><given-names>G</given-names></name><name><surname>Cifkova</surname><given-names>R</given-names></name><name><surname>Dallongeville</surname><given-names>J</given-names></name><name><surname>De Backer</surname><given-names>G</given-names></name><name><surname>Ebrahim</surname><given-names>S</given-names></name><name><surname>Gjelsvik</surname><given-names>B</given-names></name><name><surname>Herrmann-Lingen</surname><given-names>C</given-names></name><name><surname>Hoes</surname><given-names>A</given-names></name><name><surname>Humphries</surname><given-names>S</given-names></name><name><surname>Knapton</surname><given-names>M</given-names></name><name><surname>Perk</surname><given-names>J</given-names></name><name><surname>Priori</surname><given-names>SG</given-names></name><name><surname>Pyorala</surname><given-names>K</given-names></name><name><surname>Reiner</surname><given-names>Z</given-names></name><name><surname>Ruilope</surname><given-names>L</given-names></name><name><surname>Sans-Menendez</surname><given-names>S</given-names></name><name><surname>Scholte op Reimer</surname><given-names>W</given-names></name><name><surname>Weissberg</surname><given-names>P</given-names></name><name><surname>Wood</surname><given-names>D</given-names></name><name><surname>Yarnell</surname><given-names>J</given-names></name><name><surname>Zamorano</surname><given-names>JL</given-names></name><collab>Other experts who contributed to parts of the guidelines:</collab><name><surname>Walma</surname><given-names>E</given-names></name><name><surname>Fitzgerald</surname><given-names>T</given-names></name><name><surname>Cooney</surname><given-names>MT</given-names></name><name><surname>Dudina</surname><given-names>A</given-names></name><collab>European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG)</collab><name><surname>Vahanian</surname><given-names>A</given-names></name><name><surname>Camm</surname><given-names>J</given-names></name><name><surname>De Caterina</surname><given-names>R</given-names></name><name><surname>Dean</surname><given-names>V</given-names></name><name><surname>Dickstein</surname><given-names>K</given-names></name><name><surname>Funck-Brentano</surname><given-names>C</given-names></name><name><surname>Filippatos</surname><given-names>G</given-names></name><name><surname>Hellemans</surname><given-names>I</given-names></name><name><surname>Kristensen</surname><given-names>SD</given-names></name><name><surname>McGregor</surname><given-names>K</given-names></name><name><surname>Sechtem</surname><given-names>U</given-names></name><name><surname>Silber</surname><given-names>S</given-names></name><name><surname>Tendera</surname><given-names>M</given-names></name><name><surname>Widimsky</surname><given-names>P</given-names></name><name><surname>Zamorano</surname><given-names>JL</given-names></name><name><surname>Hellemans</surname><given-names>I</given-names></name><name><surname>Altiner</surname><given-names>A</given-names></name><name><surname>Bonora</surname><given-names>E</given-names></name><name><surname>Durrington</surname><given-names>PN</given-names></name><name><surname>Fagard</surname><given-names>R</given-names></name><name><surname>Giampaoli</surname><given-names>S</given-names></name><name><surname>Hemingway</surname><given-names>H</given-names></name><name><surname>Hakansson</surname><given-names>J</given-names></name><name><surname>Kjeldsen</surname><given-names>SE</given-names></name><name><surname>Larsen</surname><given-names>ML</given-names></name><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>Manolis</surname><given-names>AJ</given-names></name><name><surname>Orth-Gomer</surname><given-names>K</given-names></name><name><surname>Pedersen</surname><given-names>T</given-names></name><name><surname>Rayner</surname><given-names>M</given-names></name><name><surname>Ryden</surname><given-names>L</given-names></name><name><surname>Sammut</surname><given-names>M</given-names></name><name><surname>Schneiderman</surname><given-names>N</given-names></name><name><surname>Stalenhoef</surname><given-names>AF</given-names></name><name><surname>Tokg&#x000f6;zoglu</surname><given-names>L</given-names></name><name><surname>Wiklund</surname><given-names>O</given-names></name><name><surname>Zampelas</surname><given-names>A</given-names></name></person-group><article-title>European guidelines on cardiovascular disease prevention in clinical practice: executive summary</article-title><source>Eur Heart J</source><year>2007</year><volume>28</volume><fpage>2375</fpage><lpage>2414</lpage><pub-id pub-id-type="pmid">17726041</pub-id><pub-id pub-id-type="doi">10.1093/eurheartj/ehm316</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zintzaras</surname><given-names>E</given-names></name><name><surname>Lau</surname><given-names>J</given-names></name></person-group><article-title>Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches</article-title><source>J Clin Epidemiol</source><year>2008</year><volume>61</volume><fpage>634</fpage><lpage>645</lpage><pub-id pub-id-type="pmid">18538260</pub-id><pub-id pub-id-type="doi">10.1016/j.jclinepi.2007.12.011</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sterne</surname><given-names>JA</given-names></name><name><surname>Egger</surname><given-names>M</given-names></name></person-group><article-title>Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis</article-title><source>J Clin Epidemiol</source><year>2001</year><volume>54</volume><fpage>1046</fpage><lpage>1055</lpage><pub-id pub-id-type="pmid">11576817</pub-id><pub-id pub-id-type="doi">10.1016/S0895-4356(01)00377-8</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shanmugam</surname><given-names>V</given-names></name><name><surname>Sell</surname><given-names>KW</given-names></name><name><surname>Saha</surname><given-names>BK</given-names></name></person-group><article-title>Mistyping ACE heterozygotes</article-title><source>PCR Methods Appl</source><year>1993</year><volume>3</volume><fpage>120</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">8268786</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Volzke</surname><given-names>H</given-names></name><name><surname>Hertwig</surname><given-names>S</given-names></name><name><surname>Rettig</surname><given-names>R</given-names></name><name><surname>Motz</surname><given-names>W</given-names></name></person-group><article-title>The angiotensinogen gene 235T variant is associated with an increased risk of restenosis after percutaneous transluminal coronary angioplasty</article-title><source>Clin Sci (Lond)</source><year>2000</year><volume>99</volume><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">10887054</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Iwai</surname><given-names>N</given-names></name><name><surname>Ohmichi</surname><given-names>N</given-names></name><name><surname>Izumi</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Kinoshita</surname><given-names>M</given-names></name></person-group><article-title>D allele of the angiotensin-converting enzyme gene is a risk factor for secondary cardiac events after myocardial infarction</article-title><source>Int J Cardiol</source><year>1999</year><volume>70</volume><fpage>119</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">10454299</pub-id><pub-id pub-id-type="doi">10.1016/S0167-5273(99)00064-9</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kasi</surname><given-names>JC</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Calvino</surname><given-names>R</given-names></name><name><surname>Vazquez-Rodriguez</surname><given-names>JM</given-names></name><name><surname>Castro-Beiras</surname><given-names>A</given-names></name><name><surname>Jeffery</surname><given-names>S</given-names></name><name><surname>Carter</surname><given-names>N</given-names></name></person-group><article-title>Angiotensin-converting enzyme insertion/deletion polymorphism and restenosis after coronary angioplasty in unstable angina pectoris</article-title><source>Am J Cardiol</source><year>1996</year><volume>77</volume><fpage>875</fpage><lpage>877</lpage><pub-id pub-id-type="pmid">8623745</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9149(97)89187-4</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kamitani</surname><given-names>A</given-names></name><name><surname>Rakugi</surname><given-names>H</given-names></name><name><surname>Higaki</surname><given-names>J</given-names></name><name><surname>Ohishi</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>SJ</given-names></name><name><surname>Takami</surname><given-names>S</given-names></name><name><surname>Nakata</surname><given-names>Y</given-names></name><name><surname>Higashino</surname><given-names>Y</given-names></name><name><surname>Fujii</surname><given-names>K</given-names></name><name><surname>Mikami</surname><given-names>H</given-names></name></person-group><article-title>Enhanced predictability of myocardial infarction in Japanese by combined genotype analysis</article-title><source>Hypertension</source><year>1995</year><volume>25</volume><fpage>950</fpage><lpage>953</lpage><pub-id pub-id-type="pmid">7737732</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Samani</surname><given-names>NJ</given-names></name><name><surname>O'Toole</surname><given-names>L</given-names></name><name><surname>Martin</surname><given-names>D</given-names></name><name><surname>Rai</surname><given-names>H</given-names></name><name><surname>Fletcher</surname><given-names>S</given-names></name><name><surname>Lodwick</surname><given-names>D</given-names></name><name><surname>Thompson</surname><given-names>JR</given-names></name><name><surname>Morice</surname><given-names>AH</given-names></name><name><surname>Channer</surname><given-names>K</given-names></name><name><surname>Woods</surname><given-names>KL</given-names></name></person-group><article-title>Insertion/deletion polymorphism in the angiotensin-converting enzyme gene and risk of and prognosis after myocardial infarction</article-title><source>J Am Coll Cardiol</source><year>1996</year><volume>28</volume><fpage>338</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">8800107</pub-id><pub-id pub-id-type="doi">10.1016/0735-1097(96)00139-8</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Bockxmeer</surname><given-names>FM</given-names></name><name><surname>Mamotte</surname><given-names>CD</given-names></name><name><surname>Gibbons</surname><given-names>FA</given-names></name><name><surname>Burke</surname><given-names>V</given-names></name><name><surname>Taylor</surname><given-names>RR</given-names></name></person-group><article-title>Angiotensin-converting enzyme and apolipoprotein E genotypes and restenosis after coronary angioplasty</article-title><source>Circulation</source><year>1995</year><volume>92</volume><fpage>2066</fpage><lpage>2071</lpage><pub-id pub-id-type="pmid">7554183</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsukada</surname><given-names>K</given-names></name><name><surname>Ishimitsu</surname><given-names>T</given-names></name><name><surname>Tsuchiya</surname><given-names>N</given-names></name><name><surname>Horinaka</surname><given-names>S</given-names></name><name><surname>Matsuoka</surname><given-names>H</given-names></name></person-group><article-title>Angiotensin-converting enzyme gene polymorphism and cardiovascular endocrine system in coronary angiography patients</article-title><source>Jpn Heart J</source><year>1997</year><volume>38</volume><fpage>799</fpage><lpage>810</lpage><pub-id pub-id-type="pmid">9486933</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beohar</surname><given-names>N</given-names></name><name><surname>Damaraju</surname><given-names>S</given-names></name><name><surname>Prather</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>QT</given-names></name><name><surname>Raizner</surname><given-names>A</given-names></name><name><surname>Kleiman</surname><given-names>NS</given-names></name><name><surname>Roberts</surname><given-names>R</given-names></name><name><surname>Marian</surname><given-names>AJ</given-names></name></person-group><article-title>Angiotensin-I converting enzyme genotype DD is a risk factor for coronary artery disease</article-title><source>J Investig Med</source><year>1995</year><volume>43</volume><fpage>275</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">7614074</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zee</surname><given-names>RY</given-names></name><name><surname>Fernandez-Ortiz</surname><given-names>A</given-names></name><name><surname>Macaya</surname><given-names>C</given-names></name><name><surname>Pintor</surname><given-names>E</given-names></name><name><surname>Lindpaintner</surname><given-names>K</given-names></name><name><surname>Fernandez-Cruz</surname><given-names>A</given-names></name></person-group><article-title>Ace D/I polymorphism and incidence of post-PTCA restenosis: a prospective, angiography-based evaluation</article-title><source>Hypertension</source><year>2001</year><volume>37</volume><fpage>851</fpage><lpage>855</lpage><pub-id pub-id-type="pmid">11244007</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohishi</surname><given-names>M</given-names></name><name><surname>Fujii</surname><given-names>K</given-names></name><name><surname>Minamino</surname><given-names>T</given-names></name><name><surname>Higaki</surname><given-names>J</given-names></name><name><surname>Kamitani</surname><given-names>A</given-names></name><name><surname>Rakugi</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Mikami</surname><given-names>H</given-names></name><name><surname>Miki</surname><given-names>T</given-names></name><name><surname>Ogihara</surname><given-names>T</given-names></name></person-group><article-title>A potent genetic risk factor for restenosis</article-title><source>Nat Genet</source><year>1993</year><volume>5</volume><fpage>324</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">8298638</pub-id><pub-id pub-id-type="doi">10.1038/ng1293-324</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hertwig</surname><given-names>S</given-names></name><name><surname>Volzke</surname><given-names>H</given-names></name><name><surname>Robinson</surname><given-names>DM</given-names></name><name><surname>Motz</surname><given-names>W</given-names></name><name><surname>Rettig</surname><given-names>R</given-names></name></person-group><article-title>Angiotensinogen M235T gene polymorphism and recurrent restenosis after repeated percutaneous transluminal coronary angiography</article-title><source>Clin Sci (Lond)</source><year>2002</year><volume>103</volume><fpage>101</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">12095411</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mulder</surname><given-names>HJ</given-names></name><name><surname>van Geel</surname><given-names>PP</given-names></name><name><surname>Schalij</surname><given-names>MJ</given-names></name><name><surname>van Gilst</surname><given-names>WH</given-names></name><name><surname>Zwinderman</surname><given-names>AH</given-names></name><name><surname>Bruschke</surname><given-names>AV</given-names></name></person-group><article-title>DD ACE gene polymorphism is associated with increased coronary artery endothelial dysfunction: the PREFACE trial</article-title><source>Heart</source><year>2003</year><volume>89</volume><fpage>557</fpage><lpage>558</lpage><pub-id pub-id-type="pmid">12695469</pub-id><pub-id pub-id-type="doi">10.1136/heart.89.5.557</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wijpkema</surname><given-names>JS</given-names></name><name><surname>van Haelst</surname><given-names>PL</given-names></name><name><surname>Monraats</surname><given-names>PS</given-names></name><name><surname>Bruinenberg</surname><given-names>M</given-names></name><name><surname>Zwinderman</surname><given-names>AH</given-names></name><name><surname>Zijlstra</surname><given-names>F</given-names></name><name><surname>Steege</surname><given-names>G van der</given-names></name><name><surname>de Winter</surname><given-names>RJ</given-names></name><name><surname>Doevendans</surname><given-names>PA</given-names></name><name><surname>Waltenberger</surname><given-names>J</given-names></name><name><surname>Jukema</surname><given-names>JW</given-names></name><name><surname>Tio</surname><given-names>RA</given-names></name></person-group><article-title>Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1</article-title><source>Pharmacogenet Genomics</source><year>2006</year><volume>16</volume><fpage>331</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">16609364</pub-id><pub-id pub-id-type="doi">10.1097/01.fpc.0000205001.07054.fa</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amant</surname><given-names>C</given-names></name><name><surname>Bauters</surname><given-names>C</given-names></name><name><surname>Bodart</surname><given-names>JC</given-names></name><name><surname>Lablanche</surname><given-names>JM</given-names></name><name><surname>Grollier</surname><given-names>G</given-names></name><name><surname>Danchin</surname><given-names>N</given-names></name><name><surname>Hamon</surname><given-names>M</given-names></name><name><surname>Richard</surname><given-names>F</given-names></name><name><surname>Helbecque</surname><given-names>N</given-names></name><name><surname>McFadden</surname><given-names>EP</given-names></name><name><surname>Amouyel</surname><given-names>P</given-names></name><name><surname>Bertrand</surname><given-names>ME</given-names></name></person-group><article-title>D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting</article-title><source>Circulation</source><year>1997</year><volume>96</volume><fpage>56</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">9236417</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gomma</surname><given-names>AH</given-names></name><name><surname>Elrayess</surname><given-names>MA</given-names></name><name><surname>Knight</surname><given-names>CJ</given-names></name><name><surname>Hawe</surname><given-names>E</given-names></name><name><surname>Fox</surname><given-names>KM</given-names></name><name><surname>Humphries</surname><given-names>SE</given-names></name></person-group><article-title>The endothelial nitric oxide synthase (Glu298Asp and -786T&#x00026;gt;C) gene polymorphisms are associated with coronary in-stent restenosis</article-title><source>Eur Heart J</source><year>2002</year><volume>23</volume><fpage>1955</fpage><lpage>1962</lpage><pub-id pub-id-type="pmid">12473258</pub-id><pub-id pub-id-type="doi">10.1053/euhj.2002.3400</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>SK</given-names></name><name><surname>Cho</surname><given-names>EY</given-names></name><name><surname>Park</surname><given-names>HY</given-names></name><name><surname>Im</surname><given-names>EK</given-names></name><name><surname>Jang</surname><given-names>YS</given-names></name><name><surname>Shin</surname><given-names>GJ</given-names></name><name><surname>Shim</surname><given-names>WH</given-names></name><name><surname>Cho</surname><given-names>SY</given-names></name></person-group><article-title>Renin-angiotensin-aldosterone system (RAAS) gene polymorphism as a risk factor of coronary in-stent restenosis</article-title><source>Yonsei Med J</source><year>2002</year><volume>43</volume><fpage>461</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">12205735</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ribichini</surname><given-names>F</given-names></name><name><surname>Ferrero</surname><given-names>V</given-names></name><name><surname>Matullo</surname><given-names>G</given-names></name><name><surname>Feola</surname><given-names>M</given-names></name><name><surname>Vado</surname><given-names>A</given-names></name><name><surname>Camilla</surname><given-names>T</given-names></name><name><surname>Guarrera</surname><given-names>S</given-names></name><name><surname>Carturan</surname><given-names>S</given-names></name><name><surname>Vassanelli</surname><given-names>C</given-names></name><name><surname>Uslenghi</surname><given-names>E</given-names></name><name><surname>Piazza</surname><given-names>A</given-names></name></person-group><article-title>Association study of the I/D polymorphism and plasma angiotensin-converting enzyme (ACE) as risk factors for stent restenosis</article-title><source>Clin Sci (Lond)</source><year>2004</year><volume>107</volume><fpage>381</fpage><lpage>389</lpage><pub-id pub-id-type="pmid">15101817</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>I</given-names></name><name><surname>Yamazaki</surname><given-names>T</given-names></name><name><surname>Wagatsuma</surname><given-names>K</given-names></name><name><surname>Kurusu</surname><given-names>T</given-names></name><name><surname>Shimazu</surname><given-names>Y</given-names></name><name><surname>Takikawa</surname><given-names>K</given-names></name><name><surname>Yoshikawa</surname><given-names>M</given-names></name><name><surname>Kageyama</surname><given-names>S</given-names></name><name><surname>Mochizuki</surname><given-names>S</given-names></name></person-group><article-title>The DD genotype of angiotensin converting enzyme polymorphism is a risk factor for coronary artery disease and coronary stent restenosis in Japanese patients</article-title><source>Jpn Circ J</source><year>2001</year><volume>65</volume><fpage>897</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">11665795</pub-id><pub-id pub-id-type="doi">10.1253/jcj.65.897</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>W</given-names></name><name><surname>Kastrati</surname><given-names>A</given-names></name><name><surname>Mehilli</surname><given-names>J</given-names></name><name><surname>Bottiger</surname><given-names>C</given-names></name><name><surname>von</surname><given-names>BN</given-names></name><name><surname>Schomig</surname><given-names>A</given-names></name></person-group><article-title>Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is not associated with restenosis after coronary stent placement</article-title><source>Circulation</source><year>2000</year><volume>102</volume><fpage>197</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">10889131</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gurlek</surname><given-names>A</given-names></name><name><surname>Gulec</surname><given-names>S</given-names></name><name><surname>Karabulut</surname><given-names>H</given-names></name><name><surname>Bokesoy</surname><given-names>I</given-names></name><name><surname>Tutar</surname><given-names>E</given-names></name><name><surname>Pamir</surname><given-names>G</given-names></name><name><surname>Alpman</surname><given-names>A</given-names></name><name><surname>Toydemir</surname><given-names>R</given-names></name><name><surname>Aras</surname><given-names>O</given-names></name><name><surname>Oral</surname><given-names>D</given-names></name></person-group><article-title>Relation between the insertion/deletion polymorphism of the angiotensin I converting enzyme gene and restenosis after coronary stenting</article-title><source>J Cardiovasc Risk</source><year>2000</year><volume>7</volume><fpage>403</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">11155292</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamon</surname><given-names>M</given-names></name><name><surname>Amant</surname><given-names>C</given-names></name><name><surname>Bauters</surname><given-names>C</given-names></name><name><surname>Richard</surname><given-names>F</given-names></name><name><surname>Helbecque</surname><given-names>N</given-names></name><name><surname>Passard</surname><given-names>F</given-names></name><name><surname>McFadden</surname><given-names>EP</given-names></name><name><surname>Lablanche</surname><given-names>JM</given-names></name><name><surname>Bertrand</surname><given-names>ME</given-names></name><name><surname>Amouyel</surname><given-names>P</given-names></name></person-group><article-title>Dual determination of angiotensin-converting enzyme and angiotensin-II type 1 receptor genotypes as predictors of restenosis after coronary angioplasty</article-title><source>Am J Cardiol</source><year>1998</year><volume>81</volume><fpage>79</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">9462611</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9149(97)00852-7</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamon</surname><given-names>M</given-names></name><name><surname>Amant</surname><given-names>C</given-names></name><name><surname>Bauters</surname><given-names>C</given-names></name><name><surname>Lablanche</surname><given-names>JM</given-names></name><name><surname>Bertrand</surname><given-names>M</given-names></name><name><surname>Amouyel</surname><given-names>P</given-names></name></person-group><article-title>ACE polymorphism, a genetic predictor of occlusion after coronary angioplasty</article-title><source>Am J Cardiol</source><year>1996</year><volume>78</volume><fpage>679</fpage><lpage>681</lpage><pub-id pub-id-type="pmid">8831406</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9149(96)00395-5</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gross</surname><given-names>CM</given-names></name><name><surname>Perrot</surname><given-names>A</given-names></name><name><surname>Geier</surname><given-names>C</given-names></name><name><surname>Posch</surname><given-names>MG</given-names></name><name><surname>Hassfeld</surname><given-names>S</given-names></name><name><surname>Kramer</surname><given-names>J</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Derer</surname><given-names>W</given-names></name><name><surname>Dietz</surname><given-names>R</given-names></name><name><surname>Ozcelik</surname><given-names>C</given-names></name></person-group><article-title>Recurrent in-stent restenosis is not associated with the angiotensin-converting enzyme D/I, angiotensinogen Thr174Met and Met235Thr, and the angiotensin-II receptor 1 A1166C polymorphism</article-title><source>J Invasive Cardiol</source><year>2007</year><volume>19</volume><fpage>261</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">17541127</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamon</surname><given-names>M</given-names></name><name><surname>Fradin</surname><given-names>S</given-names></name><name><surname>Denizet</surname><given-names>A</given-names></name><name><surname>Filippi-Codaccioni</surname><given-names>E</given-names></name><name><surname>Grollier</surname><given-names>G</given-names></name><name><surname>Morello</surname><given-names>R</given-names></name></person-group><article-title>Prospective evaluation of the effect of an angiotensin I converting enzyme gene polymorphism on the long term risk of major adverse cardiac events after percutaneous coronary intervention</article-title><source>Heart</source><year>2003</year><volume>89</volume><fpage>321</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">12591842</pub-id><pub-id pub-id-type="doi">10.1136/heart.89.3.321</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prisco</surname><given-names>D</given-names></name><name><surname>Fatini</surname><given-names>C</given-names></name><name><surname>Battaglini</surname><given-names>B</given-names></name><name><surname>Gensini</surname><given-names>F</given-names></name><name><surname>Fedi</surname><given-names>S</given-names></name><name><surname>Falai</surname><given-names>M</given-names></name><name><surname>Chioccioli</surname><given-names>M</given-names></name><name><surname>Gori</surname><given-names>AM</given-names></name><name><surname>Margheri</surname><given-names>M</given-names></name><name><surname>Gensini</surname><given-names>GF</given-names></name></person-group><article-title>Angiotensin converting enzyme DD genotype affects the changes of plasma plasminogen activator inhibitor-1 activity after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction patients</article-title><source>Int J Clin Lab Res</source><year>2000</year><volume>30</volume><fpage>179</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">11289708</pub-id><pub-id pub-id-type="doi">10.1007/s005990070004</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ribichini</surname><given-names>F</given-names></name><name><surname>Wijns</surname><given-names>W</given-names></name><name><surname>Ferrero</surname><given-names>V</given-names></name><name><surname>Matullo</surname><given-names>G</given-names></name><name><surname>Camilla</surname><given-names>T</given-names></name><name><surname>Feola</surname><given-names>M</given-names></name><name><surname>Guarrera</surname><given-names>S</given-names></name><name><surname>Vado</surname><given-names>A</given-names></name><name><surname>Piazza</surname><given-names>A</given-names></name><name><surname>Uslenghi</surname><given-names>E</given-names></name></person-group><article-title>Effect of angiotensin-converting enzyme inhibition on restenosis after coronary stenting</article-title><source>Am J Cardiol</source><year>2003</year><volume>91</volume><fpage>154</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">12521626</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9149(02)03101-6</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guneri</surname><given-names>S</given-names></name><name><surname>Baris</surname><given-names>N</given-names></name><name><surname>Aytekin</surname><given-names>D</given-names></name><name><surname>Akdeniz</surname><given-names>B</given-names></name><name><surname>Pekel</surname><given-names>N</given-names></name><name><surname>Bozdemir</surname><given-names>V</given-names></name></person-group><article-title>The relationship between angiotensin converting enzyme gene polymorphism, coronary artery disease, and stent restenosis: the role of angiotensin converting enzyme inhibitors in stent restenosis in patients with diabetes mellitus</article-title><source>Int Heart J</source><year>2005</year><volume>46</volume><fpage>889</fpage><lpage>897</lpage><pub-id pub-id-type="pmid">16272779</pub-id><pub-id pub-id-type="doi">10.1536/ihj.46.889</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okamura</surname><given-names>A</given-names></name><name><surname>Ohishi</surname><given-names>M</given-names></name><name><surname>Rakugi</surname><given-names>H</given-names></name><name><surname>Katsuya</surname><given-names>T</given-names></name><name><surname>Yanagitani</surname><given-names>Y</given-names></name><name><surname>Takiuchi</surname><given-names>S</given-names></name><name><surname>Taniyama</surname><given-names>Y</given-names></name><name><surname>Moriguchi</surname><given-names>K</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name><name><surname>Higashino</surname><given-names>Y</given-names></name><name><surname>Fujii</surname><given-names>K</given-names></name><name><surname>Higaki</surname><given-names>J</given-names></name><name><surname>Ogihara</surname><given-names>T</given-names></name></person-group><article-title>Pharmacogenetic analysis of the effect of angiotensin-converting enzyme inhibitor on restenosis after percutaneous transluminal coronary angioplasty</article-title><source>Angiology</source><year>1999</year><volume>50</volume><fpage>811</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">10535720</pub-id><pub-id pub-id-type="doi">10.1177/000331979905001005</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okumura</surname><given-names>K</given-names></name><name><surname>Sone</surname><given-names>T</given-names></name><name><surname>Kondo</surname><given-names>J</given-names></name><name><surname>Tsuboi</surname><given-names>H</given-names></name><name><surname>Mukawa</surname><given-names>H</given-names></name><name><surname>Tsuzuki</surname><given-names>M</given-names></name><name><surname>Imai</surname><given-names>H</given-names></name><name><surname>Kamiya</surname><given-names>H</given-names></name><name><surname>Mabuchi</surname><given-names>Y</given-names></name><name><surname>Matsui</surname><given-names>H</given-names></name><name><surname>Hayakawa</surname><given-names>T</given-names></name></person-group><article-title>Quinapril prevents restenosis after coronary stenting in patients with angiotensin-converting enzyme D allele</article-title><source>Circ J</source><year>2002</year><volume>66</volume><fpage>311</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">11954942</pub-id><pub-id pub-id-type="doi">10.1253/circj.66.311</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>M</given-names></name><name><surname>Mudra</surname><given-names>H</given-names></name><name><surname>Grip</surname><given-names>L</given-names></name><name><surname>Voudris</surname><given-names>V</given-names></name><name><surname>Schachinger</surname><given-names>V</given-names></name><name><surname>de Jaegere</surname><given-names>P</given-names></name><name><surname>Rieber</surname><given-names>J</given-names></name><name><surname>Hausmann</surname><given-names>D</given-names></name><name><surname>Rothman</surname><given-names>M</given-names></name><name><surname>Koschyk</surname><given-names>DH</given-names></name><name><surname>Figulla</surname><given-names>HR</given-names></name><collab>OPTICUS ACE Substudy</collab></person-group><article-title>Angiotensin-converting enzyme insertion/deletion polymorphism does not influence the restenosis rate after coronary stent implantation</article-title><source>Cardiology</source><year>2002</year><volume>97</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">11893827</pub-id><pub-id pub-id-type="doi">10.1159/000047416</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>W</given-names></name><name><surname>Mehilli</surname><given-names>J</given-names></name><name><surname>von</surname><given-names>BN</given-names></name><name><surname>Bottiger</surname><given-names>C</given-names></name><name><surname>Schomig</surname><given-names>A</given-names></name><name><surname>Kastrati</surname><given-names>A</given-names></name></person-group><article-title>Angiotensin I-converting enzyme (ACE) inhibitors and restenosis after coronary artery stenting in patients with the DD genotype of the ACE gene</article-title><source>J Am Coll Cardiol</source><year>2003</year><volume>41</volume><fpage>1957</fpage><lpage>1961</lpage><pub-id pub-id-type="pmid">12798565</pub-id><pub-id pub-id-type="doi">10.1016/S0735-1097(03)00406-6</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meurice</surname><given-names>T</given-names></name><name><surname>Bauters</surname><given-names>C</given-names></name><name><surname>Hermant</surname><given-names>X</given-names></name><name><surname>Codron</surname><given-names>V</given-names></name><name><surname>VanBelle</surname><given-names>E</given-names></name><name><surname>Mc Fadden</surname><given-names>EP</given-names></name><name><surname>Lablanche</surname><given-names>J</given-names></name><name><surname>Bertrand</surname><given-names>ME</given-names></name><name><surname>Amouyel</surname><given-names>P</given-names></name></person-group><article-title>Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial</article-title><source>Lancet</source><year>2001</year><volume>357</volume><fpage>1321</fpage><lpage>1324</lpage><pub-id pub-id-type="pmid">11343737</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(00)04518-9</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jorgensen</surname><given-names>E</given-names></name><name><surname>Kelbaek</surname><given-names>H</given-names></name><name><surname>Helqvist</surname><given-names>S</given-names></name><name><surname>Jensen</surname><given-names>GV</given-names></name><name><surname>Saunamaki</surname><given-names>K</given-names></name><name><surname>Kastrup</surname><given-names>J</given-names></name><name><surname>Havndrup</surname><given-names>O</given-names></name><name><surname>Bundgaard</surname><given-names>H</given-names></name><name><surname>Kyst Madsen</surname><given-names>J</given-names></name><name><surname>Christiansen</surname><given-names>M</given-names></name><name><surname>Andersen</surname><given-names>PS</given-names></name><name><surname>Reiber</surname><given-names>JH</given-names></name></person-group><article-title>Predictors of coronary in-stent restenosis: importance of angiotensin-converting enzyme gene polymorphism and treatment with angiotensin-converting enzyme inhibitors</article-title><source>J Am Coll Cardiol</source><year>2001</year><volume>38</volume><fpage>1434</fpage><lpage>1439</lpage><pub-id pub-id-type="pmid">11691520</pub-id><pub-id pub-id-type="doi">10.1016/S0735-1097(01)01580-7</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Toyofyuku</surname><given-names>M</given-names></name><name><surname>Imazu</surname><given-names>M</given-names></name><name><surname>Sumii</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Hayashi</surname><given-names>Y</given-names></name><name><surname>Hiyama</surname><given-names>K</given-names></name><name><surname>Kohno</surname><given-names>N</given-names></name></person-group><article-title>Influence of angiotensinogen M253T gene polymorphism and an angiotensin converting enzyme inhibitor on restenosis after percutaneous coronary intervention</article-title><source>Atherosclerosis</source><year>2002</year><volume>160</volume><fpage>339</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">11849656</pub-id><pub-id pub-id-type="doi">10.1016/S0021-9150(01)00592-5</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haberbosch</surname><given-names>W</given-names></name><name><surname>Bohle</surname><given-names>RM</given-names></name><name><surname>Franke</surname><given-names>FE</given-names></name><name><surname>Danilov</surname><given-names>S</given-names></name><name><surname>henc-Gelas</surname><given-names>F</given-names></name><name><surname>Braun-Dullaeus</surname><given-names>R</given-names></name><name><surname>H&#x000f6;lschermann</surname><given-names>H</given-names></name><name><surname>Waas</surname><given-names>W</given-names></name><name><surname>Tillmanns</surname><given-names>H</given-names></name><name><surname>Gardemann</surname><given-names>A</given-names></name></person-group><article-title>The expression of angiotensin-I converting enzyme in human atherosclerotic plaques is not related to the deletion/insertion polymorphism but to the risk of restenosis after coronary interventions</article-title><source>Atherosclerosis</source><year>1997</year><volume>130</volume><fpage>203</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">9126666</pub-id><pub-id pub-id-type="doi">10.1016/S0021-9150(96)06058-3</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Canosi</surname><given-names>U</given-names></name><name><surname>Angelica Merlini</surname><given-names>P</given-names></name><name><surname>Bernardi</surname><given-names>F</given-names></name><name><surname>Repetto</surname><given-names>A</given-names></name><name><surname>Bramucci</surname><given-names>E</given-names></name><name><surname>Ferrario</surname><given-names>M</given-names></name><name><surname>Angoli</surname><given-names>L</given-names></name><name><surname>Gnecchi</surname><given-names>M</given-names></name><name><surname>Ferraresi</surname><given-names>P</given-names></name><name><surname>Marchetti</surname><given-names>G</given-names></name><name><surname>Tavazzi</surname><given-names>L</given-names></name><name><surname>Ardissino</surname><given-names>D</given-names></name></person-group><article-title>Angiotensin-converting enzyme insertion/deletion polymorphism and risk of restenosis after directional coronary atherectomy followed by stent implantation</article-title><source>Thromb Haemost</source><year>2004</year><volume>91</volume><fpage>795</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">15045142</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dayi</surname><given-names>SU</given-names></name><name><surname>Tartan</surname><given-names>Z</given-names></name><name><surname>Terzi</surname><given-names>S</given-names></name><name><surname>Kasikcioglu</surname><given-names>H</given-names></name><name><surname>Uyarel</surname><given-names>H</given-names></name><name><surname>Orhan</surname><given-names>G</given-names></name><name><surname>Alper</surname><given-names>AT</given-names></name><name><surname>Ciloglu</surname><given-names>F</given-names></name><name><surname>Cam</surname><given-names>N</given-names></name></person-group><article-title>Influence of angiotensin converting enzyme insertion/deletion polymorphism on long-term total graft occlusion after coronary artery bypass surgery</article-title><source>Heart Surg Forum</source><year>2005</year><volume>8</volume><fpage>E373</fpage><lpage>E377</lpage><pub-id pub-id-type="pmid">16146835</pub-id><pub-id pub-id-type="doi">10.1532/HSF98.20051113</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ortlepp</surname><given-names>JR</given-names></name><name><surname>Janssens</surname><given-names>U</given-names></name><name><surname>Bleckmann</surname><given-names>F</given-names></name><name><surname>Lauscher</surname><given-names>J</given-names></name><name><surname>Merkelbach-Bruse</surname><given-names>S</given-names></name><name><surname>Hanrath</surname><given-names>P</given-names></name><name><surname>Hoffmann</surname><given-names>R</given-names></name></person-group><article-title>A chymase gene variant is associated with atherosclerosis in venous coronary artery bypass grafts</article-title><source>Coron Artery Dis</source><year>2001</year><volume>12</volume><fpage>493</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">11696688</pub-id><pub-id pub-id-type="doi">10.1097/00019501-200109000-00008</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Volzke</surname><given-names>H</given-names></name><name><surname>Engel</surname><given-names>J</given-names></name><name><surname>Kleine</surname><given-names>V</given-names></name><name><surname>Schwahn</surname><given-names>C</given-names></name><name><surname>Dahm</surname><given-names>JB</given-names></name><name><surname>Eckel</surname><given-names>L</given-names></name><name><surname>Rettig</surname><given-names>R</given-names></name></person-group><article-title>Angiotensin I-converting enzyme insertion/deletion polymorphism and cardiac mortality and morbidity after coronary artery bypass graft surgery</article-title><source>Chest</source><year>2002</year><volume>122</volume><fpage>31</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">12114335</pub-id><pub-id pub-id-type="doi">10.1378/chest.122.1.31</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Voors</surname><given-names>AA</given-names></name><name><surname>van Geel</surname><given-names>PP</given-names></name><name><surname>Oosterga</surname><given-names>M</given-names></name><name><surname>Buikema</surname><given-names>H</given-names></name><name><surname>van Veldhuisen</surname><given-names>DJ</given-names></name><name><surname>van Gilst</surname><given-names>WH</given-names></name></person-group><article-title>Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism</article-title><source>J Renin Angiotensin Aldosterone Syst</source><year>2004</year><volume>5</volume><fpage>130</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">15526248</pub-id><pub-id pub-id-type="doi">10.3317/jraas.2004.029</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnett</surname><given-names>DK</given-names></name><name><surname>Davis</surname><given-names>BR</given-names></name><name><surname>Ford</surname><given-names>CE</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Leiendecker-Foster</surname><given-names>C</given-names></name><name><surname>Miller</surname><given-names>MB</given-names></name><name><surname>Black</surname><given-names>H</given-names></name><name><surname>Eckfeldt</surname><given-names>JH</given-names></name></person-group><article-title>Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study</article-title><source>Circulation</source><year>2005</year><volume>111</volume><fpage>3374</fpage><lpage>3383</lpage><pub-id pub-id-type="pmid">15967849</pub-id><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.104.504639</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harrap</surname><given-names>SB</given-names></name><name><surname>Tzourio</surname><given-names>C</given-names></name><name><surname>Cambien</surname><given-names>F</given-names></name><name><surname>Poirier</surname><given-names>O</given-names></name><name><surname>Raoux</surname><given-names>S</given-names></name><name><surname>Chalmers</surname><given-names>J</given-names></name><name><surname>Chapman</surname><given-names>N</given-names></name><name><surname>Colman</surname><given-names>S</given-names></name><name><surname>Leguennec</surname><given-names>S</given-names></name><name><surname>MacMahon</surname><given-names>S</given-names></name><name><surname>Neal</surname><given-names>B</given-names></name><name><surname>Ohkubo</surname><given-names>T</given-names></name><name><surname>Woodward</surname><given-names>M</given-names></name><collab>PROGRESS Collaborative Group</collab></person-group><article-title>The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition</article-title><source>Hypertension</source><year>2003</year><volume>42</volume><fpage>297</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">12925557</pub-id><pub-id pub-id-type="doi">10.1161/01.HYP.0000088322.85804.96</pub-id></citation></ref><ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marciante</surname><given-names>KD</given-names></name><name><surname>Bis</surname><given-names>JC</given-names></name><name><surname>Rieder</surname><given-names>MJ</given-names></name><name><surname>Reiner</surname><given-names>AP</given-names></name><name><surname>Lumley</surname><given-names>T</given-names></name><name><surname>Monks</surname><given-names>SA</given-names></name><name><surname>Kooperberg</surname><given-names>C</given-names></name><name><surname>Carlson</surname><given-names>C</given-names></name><name><surname>Heckbert</surname><given-names>SR</given-names></name><name><surname>Psaty</surname><given-names>BM</given-names></name></person-group><article-title>Renin-angiotensin system haplotypes and the risk of myocardial infarction and stroke in pharmacologically treated hypertensive patients</article-title><source>Am J Epidemiol</source><year>2007</year><volume>166</volume><fpage>19</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">17522061</pub-id><pub-id pub-id-type="doi">10.1093/aje/kwm059</pub-id></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>YM</given-names></name><name><surname>van Gilst</surname><given-names>WH</given-names></name><name><surname>Kingma</surname><given-names>JH</given-names></name><name><surname>Schunkert</surname><given-names>H</given-names></name></person-group><article-title>Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. Captopril and Thrombolysis Study Investigators</article-title><source>J Am Coll Cardiol</source><year>1995</year><volume>25</volume><fpage>1622</fpage><lpage>1626</lpage><pub-id pub-id-type="pmid">7759715</pub-id><pub-id pub-id-type="doi">10.1016/0735-1097(95)00090-Q</pub-id></citation></ref><ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zee</surname><given-names>RY</given-names></name><name><surname>Solomon</surname><given-names>SD</given-names></name><name><surname>Ajani</surname><given-names>UA</given-names></name><name><surname>Pfeffer</surname><given-names>MA</given-names></name><name><surname>Lindpaintner</surname><given-names>K</given-names></name></person-group><article-title>A prospective evaluation of the angiotensin-converting enzyme D/I polymorphism and left ventricular remodeling in the 'Healing and Early Afterload Reducing Therapy' study</article-title><source>Clin Genet</source><year>2002</year><volume>61</volume><fpage>21</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">11903350</pub-id><pub-id pub-id-type="doi">10.1034/j.1399-0004.2002.610104.x</pub-id></citation></ref><ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kennon</surname><given-names>S</given-names></name><name><surname>Barakat</surname><given-names>K</given-names></name><name><surname>Hitman</surname><given-names>GA</given-names></name><name><surname>Price</surname><given-names>CP</given-names></name><name><surname>Mills</surname><given-names>PG</given-names></name><name><surname>Ranjadayalan</surname><given-names>K</given-names></name><name><surname>Cooper</surname><given-names>J</given-names></name><name><surname>Clark</surname><given-names>H</given-names></name><name><surname>Timmis</surname><given-names>AD</given-names></name></person-group><article-title>Angiotensin-converting enzyme inhibition is associated with reduced troponin release in non-ST-elevation acute coronary syndromes</article-title><source>J Am Coll Cardiol</source><year>2001</year><volume>38</volume><fpage>724</fpage><lpage>728</lpage><pub-id pub-id-type="pmid">11527624</pub-id><pub-id pub-id-type="doi">10.1016/S0735-1097(01)01426-7</pub-id></citation></ref><ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>A</given-names></name><name><surname>Narayanan</surname><given-names>S</given-names></name><name><surname>Husain</surname><given-names>S</given-names></name><name><surname>Padder</surname><given-names>F</given-names></name><name><surname>Waclawiw</surname><given-names>M</given-names></name><name><surname>Epstein</surname><given-names>N</given-names></name><name><surname>Quyyumi</surname><given-names>AA</given-names></name></person-group><article-title>Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition</article-title><source>Circulation</source><year>2000</year><volume>102</volume><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">10880412</pub-id></citation></ref><ref id="B64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trevelyan</surname><given-names>J</given-names></name><name><surname>Needham</surname><given-names>EW</given-names></name><name><surname>Morris</surname><given-names>A</given-names></name><name><surname>Mattu</surname><given-names>RK</given-names></name></person-group><article-title>Comparison of the effect of enalapril and losartan in conjunction with surgical coronary revascularisation versus revascularisation alone on systemic endothelial function</article-title><source>Heart</source><year>2005</year><volume>91</volume><fpage>1053</fpage><lpage>1057</lpage><pub-id pub-id-type="pmid">16020596</pub-id><pub-id pub-id-type="doi">10.1136/hrt.2004.036897</pub-id></citation></ref><ref id="B65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>OD</given-names></name><name><surname>Gram</surname><given-names>J</given-names></name><name><surname>Jeunemaitre</surname><given-names>X</given-names></name><name><surname>Billaud</surname><given-names>E</given-names></name><name><surname>Jespersen</surname><given-names>J</given-names></name></person-group><article-title>Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction</article-title><source>Coron Artery Dis</source><year>1997</year><volume>8</volume><fpage>283</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">9285181</pub-id><pub-id pub-id-type="doi">10.1097/00019501-199705000-00005</pub-id></citation></ref><ref id="B66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jeron</surname><given-names>A</given-names></name><name><surname>Hengstenberg</surname><given-names>C</given-names></name><name><surname>Engel</surname><given-names>S</given-names></name><name><surname>Lowel</surname><given-names>H</given-names></name><name><surname>Riegger</surname><given-names>GA</given-names></name><name><surname>Schunkert</surname><given-names>H</given-names></name><name><surname>Holmer</surname><given-names>S</given-names></name></person-group><article-title>The D-allele of the ACE polymorphism is related to increased QT dispersion in 609 patients after myocardial infarction</article-title><source>Eur Heart J</source><year>2001</year><volume>22</volume><fpage>663</fpage><lpage>668</lpage><pub-id pub-id-type="pmid">11286523</pub-id><pub-id pub-id-type="doi">10.1053/euhj.2000.2297</pub-id></citation></ref><ref id="B67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steeds</surname><given-names>RP</given-names></name><name><surname>Fletcher</surname><given-names>J</given-names></name><name><surname>Parry</surname><given-names>H</given-names></name><name><surname>Chowdhary</surname><given-names>S</given-names></name><name><surname>Channer</surname><given-names>KS</given-names></name><name><surname>West</surname><given-names>J</given-names></name><name><surname>Townend</surname><given-names>JN</given-names></name></person-group><article-title>The angiotensin-converting enzyme gene I/D polymorphism and heart rate variability following acute myocardial infarction</article-title><source>Clin Auton Res</source><year>2002</year><volume>12</volume><fpage>66</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">12102452</pub-id><pub-id pub-id-type="doi">10.1007/s102860200022</pub-id></citation></ref><ref id="B68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zee</surname><given-names>AH Maitland-van der</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Arnett</surname><given-names>DK</given-names></name><name><surname>Davis</surname><given-names>BR</given-names></name><name><surname>Leiendecker-Foster</surname><given-names>C</given-names></name><name><surname>Miller</surname><given-names>MB</given-names></name><name><surname>Klungel</surname><given-names>OH</given-names></name><name><surname>Ford</surname><given-names>CE</given-names></name><name><surname>Eckfeldt</surname><given-names>JH</given-names></name></person-group><article-title>Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study</article-title><source>Am Heart J</source><year>2007</year><volume>153</volume><fpage>54</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">17174637</pub-id><pub-id pub-id-type="doi">10.1016/j.ahj.2006.10.019</pub-id></citation></ref><ref id="B69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zee</surname><given-names>AH Maitland-van der</given-names></name><name><surname>Stricker</surname><given-names>BH</given-names></name><name><surname>Klungel</surname><given-names>OH</given-names></name><name><surname>Kastelein</surname><given-names>JJ</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Witteman</surname><given-names>JC</given-names></name><name><surname>Leufkens</surname><given-names>HG</given-names></name><name><surname>Duijn</surname><given-names>CM</given-names></name><name><surname>Boer</surname><given-names>AdA</given-names></name></person-group><article-title>Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism</article-title><source>Atherosclerosis</source><year>2004</year><volume>175</volume><fpage>377</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">15262195</pub-id><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2004.01.042</pub-id></citation></ref><ref id="B70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>PF</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Goldschmidt-Clermont</surname><given-names>P</given-names></name><name><surname>Moye</surname><given-names>LA</given-names></name><name><surname>Pfeffer</surname><given-names>MA</given-names></name><name><surname>Sacks</surname><given-names>FM</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name></person-group><article-title>The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction</article-title><source>Am J Cardiol</source><year>2001</year><volume>88</volume><fpage>347</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">11545752</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9149(01)01677-0</pub-id></citation></ref><ref id="B71"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marian</surname><given-names>AJ</given-names></name><name><surname>Safavi</surname><given-names>F</given-names></name><name><surname>Ferlic</surname><given-names>L</given-names></name><name><surname>Dunn</surname><given-names>JK</given-names></name><name><surname>Gotto</surname><given-names>AM</given-names></name><name><surname>Ballantyne</surname><given-names>CM</given-names></name></person-group><article-title>Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study</article-title><source>J Am Coll Cardiol</source><year>2000</year><volume>35</volume><fpage>89</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">10636265</pub-id><pub-id pub-id-type="doi">10.1016/S0735-1097(99)00535-5</pub-id></citation></ref><ref id="B72"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Talmud</surname><given-names>PJ</given-names></name><name><surname>Watts</surname><given-names>GF</given-names></name><name><surname>McBride</surname><given-names>S</given-names></name><name><surname>Mandalia</surname><given-names>S</given-names></name><name><surname>Brunt</surname><given-names>JN</given-names></name><name><surname>Coltart</surname><given-names>DJ</given-names></name><name><surname>Lewis</surname><given-names>B</given-names></name><name><surname>Humphries</surname><given-names>SE</given-names></name></person-group><article-title>Angiotensin converting enzyme gene polymorphism and the course of angiographically defined coronary artery disease</article-title><source>Atherosclerosis</source><year>1995</year><volume>114</volume><fpage>133</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">7605372</pub-id><pub-id pub-id-type="doi">10.1016/0021-9150(94)05467-W</pub-id></citation></ref><ref id="B73"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Defoor</surname><given-names>J</given-names></name><name><surname>Vanhees</surname><given-names>L</given-names></name><name><surname>Martens</surname><given-names>K</given-names></name><name><surname>Matthijs</surname><given-names>G</given-names></name><name><surname>Van</surname><given-names>VA</given-names></name><name><surname>Zielinska</surname><given-names>D</given-names></name><name><surname>Schepers</surname><given-names>D</given-names></name><name><surname>Vlietinck</surname><given-names>R</given-names></name><name><surname>Fagard</surname><given-names>R</given-names></name></person-group><article-title>The CAREGENE study: ACE gene I/D polymorphism and effect of physical training on aerobic power in coronary artery disease</article-title><source>Heart</source><year>2006</year><volume>92</volume><fpage>527</fpage><lpage>528</lpage><pub-id pub-id-type="pmid">16085717</pub-id><pub-id pub-id-type="doi">10.1136/hrt.2004.054312</pub-id></citation></ref><ref id="B74"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iwanaga</surname><given-names>Y</given-names></name><name><surname>Nishi</surname><given-names>I</given-names></name><name><surname>Ono</surname><given-names>K</given-names></name><name><surname>Takagi</surname><given-names>S</given-names></name><name><surname>Tsutsumi</surname><given-names>Y</given-names></name><name><surname>Ozaki</surname><given-names>M</given-names></name><name><surname>Noguchi</surname><given-names>T</given-names></name><name><surname>Takaki</surname><given-names>H</given-names></name><name><surname>Iwai</surname><given-names>N</given-names></name><name><surname>Nonogi</surname><given-names>H</given-names></name><name><surname>Goto</surname><given-names>Y</given-names></name></person-group><article-title>Angiotensin-converting enzyme genotype is not associated with exercise capacity or the training effect of cardiac rehabilitation in patients after acute myocardial infarction</article-title><source>Circ J</source><year>2005</year><volume>69</volume><fpage>1315</fpage><lpage>1319</lpage><pub-id pub-id-type="pmid">16247204</pub-id><pub-id pub-id-type="doi">10.1253/circj.69.1315</pub-id></citation></ref><ref id="B75"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kastrati</surname><given-names>A</given-names></name><name><surname>Mehilli</surname><given-names>J</given-names></name><name><surname>Pache</surname><given-names>J</given-names></name><name><surname>Kaiser</surname><given-names>C</given-names></name><name><surname>Valgimigli</surname><given-names>M</given-names></name><name><surname>Kelbaek</surname><given-names>H</given-names></name><name><surname>Menichelli</surname><given-names>M</given-names></name><name><surname>Sabat&#x000e9;</surname><given-names>M</given-names></name><name><surname>Suttorp</surname><given-names>MJ</given-names></name><name><surname>Baumgart</surname><given-names>D</given-names></name><name><surname>Seyfarth</surname><given-names>M</given-names></name><name><surname>Pfisterer</surname><given-names>ME</given-names></name><name><surname>Sch&#x000f6;mig</surname><given-names>A</given-names></name></person-group><article-title>Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><fpage>1030</fpage><lpage>1039</lpage><pub-id pub-id-type="pmid">17296823</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa067484</pub-id></citation></ref><ref id="B76"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Betriu</surname><given-names>A</given-names></name><name><surname>Masotti</surname><given-names>M</given-names></name><name><surname>Serra</surname><given-names>A</given-names></name><name><surname>Alonso</surname><given-names>J</given-names></name><name><surname>Fernandez-Aviles</surname><given-names>F</given-names></name><name><surname>Gimeno</surname><given-names>F</given-names></name><name><surname>Colman</surname><given-names>T</given-names></name><name><surname>Zueco</surname><given-names>J</given-names></name><name><surname>Delcan</surname><given-names>JL</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>E</given-names></name><name><surname>Calabuig</surname><given-names>J</given-names></name></person-group><article-title>Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up</article-title><source>J Am Coll Cardiol</source><year>1999</year><volume>34</volume><fpage>1498</fpage><lpage>1506</lpage><pub-id pub-id-type="pmid">10551699</pub-id><pub-id pub-id-type="doi">10.1016/S0735-1097(99)00366-6</pub-id></citation></ref><ref id="B77"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keavney</surname><given-names>B</given-names></name></person-group><article-title>Outcome following percutaneous coronary intervention: not, so far, in our genes</article-title><source>Heart</source><year>2003</year><volume>89</volume><fpage>247</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">12591817</pub-id><pub-id pub-id-type="doi">10.1136/heart.89.3.247</pub-id></citation></ref><ref id="B78"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Welt</surname><given-names>FG</given-names></name><name><surname>Rogers</surname><given-names>C</given-names></name></person-group><article-title>Inflammation and restenosis in the stent era</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2002</year><volume>22</volume><fpage>1769</fpage><lpage>1776</lpage><pub-id pub-id-type="pmid">12426203</pub-id><pub-id pub-id-type="doi">10.1161/01.ATV.0000037100.44766.5B</pub-id></citation></ref><ref id="B79"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McKenzie</surname><given-names>CA</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name><name><surname>Keavney</surname><given-names>B</given-names></name><name><surname>Forrester</surname><given-names>T</given-names></name><name><surname>Ratcliffe</surname><given-names>PJ</given-names></name><name><surname>Julier</surname><given-names>C</given-names></name><name><surname>Connell</surname><given-names>JM</given-names></name><name><surname>Bennett</surname><given-names>F</given-names></name><name><surname>McFarlane-Anderson</surname><given-names>N</given-names></name><name><surname>Lathrop</surname><given-names>GM</given-names></name><name><surname>Cardon</surname><given-names>LR</given-names></name></person-group><article-title>Trans-ethnic fine mapping of a quantitative trait locus for circulating angiotensin I-converting enzyme (ACE)</article-title><source>Hum Mol Genet</source><year>2001</year><volume>10</volume><fpage>1077</fpage><lpage>1084</lpage><pub-id pub-id-type="pmid">11331618</pub-id><pub-id pub-id-type="doi">10.1093/hmg/10.10.1077</pub-id></citation></ref><ref id="B80"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dhawan</surname><given-names>J</given-names></name><name><surname>Bray</surname><given-names>CL</given-names></name></person-group><article-title>Are Asian coronary arteries smaller than Caucasian? A study on angiographic coronary artery size estimation during life</article-title><source>Int J Cardiol</source><year>1995</year><volume>49</volume><fpage>267</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">7649673</pub-id><pub-id pub-id-type="doi">10.1016/0167-5273(95)02315-N</pub-id></citation></ref><ref id="B81"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balk</surname><given-names>EM</given-names></name><name><surname>Bonis</surname><given-names>PA</given-names></name><name><surname>Moskowitz</surname><given-names>H</given-names></name><name><surname>Schmid</surname><given-names>CH</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Lau</surname><given-names>J</given-names></name></person-group><article-title>Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials</article-title><source>JAMA</source><year>2002</year><volume>287</volume><fpage>2973</fpage><lpage>2982</lpage><pub-id pub-id-type="pmid">12052127</pub-id><pub-id pub-id-type="doi">10.1001/jama.287.22.2973</pub-id></citation></ref><ref id="B82"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bavry</surname><given-names>AA</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name></person-group><article-title>Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis</article-title><source>Lancet</source><year>2008</year><volume>371</volume><fpage>2134</fpage><lpage>2143</lpage><pub-id pub-id-type="pmid">18572082</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(08)60922-8</pub-id></citation></ref><ref id="B83"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Bouzekri</surname><given-names>N</given-names></name><name><surname>Southam</surname><given-names>L</given-names></name><name><surname>Cooper</surname><given-names>RS</given-names></name><name><surname>Adeyemo</surname><given-names>A</given-names></name><name><surname>McKenzie</surname><given-names>CA</given-names></name><name><surname>Luke</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Elston</surname><given-names>RC</given-names></name><name><surname>Ward</surname><given-names>R</given-names></name></person-group><article-title>Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure</article-title><source>Am J Hum Genet</source><year>2001</year><volume>68</volume><fpage>1139</fpage><lpage>1148</lpage><pub-id pub-id-type="pmid">11283791</pub-id><pub-id pub-id-type="doi">10.1086/320104</pub-id></citation></ref><ref id="B84"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cordell</surname><given-names>HJ</given-names></name></person-group><article-title>Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans</article-title><source>Hum Mol Genet</source><year>2002</year><volume>11</volume><fpage>2463</fpage><lpage>2468</lpage><pub-id pub-id-type="pmid">12351582</pub-id><pub-id pub-id-type="doi">10.1093/hmg/11.20.2463</pub-id></citation></ref><ref id="B85"><citation citation-type="journal"><person-group person-group-type="author"><collab>SEARCH Collaborative Group</collab><name><surname>Link</surname><given-names>E</given-names></name><name><surname>Parish</surname><given-names>S</given-names></name><name><surname>Armitage</surname><given-names>J</given-names></name><name><surname>Bowman</surname><given-names>L</given-names></name><name><surname>Heath</surname><given-names>S</given-names></name><name><surname>Matsuda</surname><given-names>F</given-names></name><name><surname>Gut</surname><given-names>I</given-names></name><name><surname>Lathrop</surname><given-names>M</given-names></name><name><surname>Collins</surname><given-names>R</given-names></name></person-group><article-title>SLCO1B1 variants and statin-induced myopathy &#x02013; a genomewide study</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>789</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">18650507</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa0801936</pub-id></citation></ref><ref id="B86"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Veenstra</surname><given-names>DL</given-names></name><name><surname>Higashi</surname><given-names>MK</given-names></name><name><surname>Phillips</surname><given-names>KA</given-names></name></person-group><article-title>Assessing the cost-effectiveness of pharmacogenomics</article-title><source>AAPS PharmSci</source><year>2000</year><volume>2</volume><fpage>E29</fpage><pub-id pub-id-type="pmid">11741245</pub-id><pub-id pub-id-type="doi">10.1208/ps020329</pub-id></citation></ref><ref id="B87"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zee</surname><given-names>AH Maitland-van der</given-names></name><name><surname>Klungel</surname><given-names>OH</given-names></name><name><surname>Stricker</surname><given-names>BH</given-names></name><name><surname>Veenstra</surname><given-names>DL</given-names></name><name><surname>Kastelein</surname><given-names>JJ</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Witteman</surname><given-names>JC</given-names></name><name><surname>Leufkens</surname><given-names>HG</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>de Boer</surname><given-names>A</given-names></name></person-group><article-title>Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men</article-title><source>Pharmacogenetics</source><year>2004</year><volume>14</volume><fpage>53</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">15128051</pub-id><pub-id pub-id-type="doi">10.1097/00008571-200401000-00006</pub-id></citation></ref></ref-list></back></article> 